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ABSTRACT

The type III secretion system of gram-negative bacterial pathogens is a
major virulence factor and functions to modulate host immune responses.
Immune modulation occurs in many ways, including direct injection of effector
proteins or indirect methods such as the detection of bacterial components by
host immune receptors. Knowledge of these immune modulations allows for
development of treatment options in an ever-increasing antibiotic-resistance
climate. The studies presented here explore both areas of immune modulation.
We identify Compound D as a potent inhibitor of the type III secretion system of
Yersinia pestis. Through evaluation of effector secretion by bacteria grown in the
presence of Compound D, we establish that inhibition of secretion occurs through
translocon protein YopD and is also affected by LcrQ and YopD’s chaperone,
LcrH. Type III Secretion inhibition by Compound D also requires a secretion
active state of the type III secretion system as determined by analysis of strains
that constitutively secrete effectors. The other study focuses on host recognition
of bacterial proteins, specifically the needle protein of type III secretion systems.
Via utilization of cells that secrete a measurable signal protein when NF-κB or
AP-1 is activated, we show that needle proteins from Yersinia pestis, Salmonella
enterica serovar Typhimurium, and Shigella flexneri are capable of activating cells
through Toll-like receptors 2 and 4. This interaction appears to be modulated by
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the N-terminus, that is reported to reside on the outside of the fully formed needle
structure, exposed to host receptors. Activation of NF-κB/AP-1 correlates with
production of TNF-α in response to needle proteins.
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CHAPTER I
INTRODUCTION

Type III Secretion Systems
In order to manipulate the host, gram-negative bacteria utilize a number of
features. One of these essential virulence factors is the type three-secretion
system (T3SS). T3S systems are important in several known symbiotic
relationships, demonstrating a duality of T3S functions ranging from beneficial to
detrimental manipulation of eukaryotic cells (39, 87). T3SSs are found in many
human pathogenic gram- negative bacteria including pathogenic strains of
Escherichia coli, Shigella, Salmonella, Yersinia, and Pseudomonas (24, 71).
T3SSs are divided into seven families based on sequence similarities. T3SSs
from animal pathogens fall into three of those families: Ysc-type injectisomes,
SPI-1-type injectisomes, or SPI-2-type injectisomes. Although much of the basal
structures of these systems are homologous, the secreted effectors and
regulation of secretion vary between each family. Ysc injectisomes are primarily
found in Yersinia species, P. aeruginosa, Vibrio, and Bordetella pertussis. SPI-1
injectisomes are commonly associated with Shigella and Salmonella. SPI-2
injectisomes are associated with enterohemorraghic E. coli (EHEC),
enteropathogenic E. coli (EPEC), and Salmonella. Many structural proteins of the
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T3SS are homologous between these families; those proteins that are not
homologous often still have an analogous protein with an equivalent function
(24).
Structure
The T3SS is comprised of approximately 25 different proteins that make
up the basal body, needle, and translocon (24). The basal body embeds in the
inner and outer bacterial membrane via two ring-like structures connected by a
rod structure (Figure 1) (71). The basal structural components are largely
conserved between T3SSs, including bacterial flagella (24). On the cytosolic
side of the basal structure an ATPase can be found that is critical for secretion of
proteins (24). The internal channel of the T3SS is about 2-3 nm, only big enough
for unfolded proteins to pass through (24). The number of needle complexes per
bacteria varies, from 10-100 complexes, depending on the species (42).
Extending out from the basal structure is a hollow needle (24). This
portion of the secretion system is made up of repeating subunits of one protein
and a cap protein that sits at the tip (73). The sequence of needle proteins is
largely conserved between bacterial species, except the N-terminus. X-ray
crystallography and NMR have been utilized to detect structures of some needle
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Figure 1. Type III secretion system structure. (Used with Permission) (50)
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proteins, including MxiH from Shigella (27), BsaL from Burkholderia pseudomallei
(108), and PrgI from Salmonella enterica serovar Typhimurium (S. Typhimurium)
(108). The crystal structure of MxiH was used to generate a model of the T3S
needle structure (7, 22, 27). The MxiH-derived model of the needle protein
possesses two coiled domains with the N-terminus of the needle protein predicted
to line the lumen of the T3S needle (27). The N-terminus of the needle protein in
all these cases was seen to be highly mobile and disordered (8, 108) offering little
data to define structures of this portion of the protein. Sun et al. reported the Nterminus in their crystal structure to be largely unorganized and not representative
of the protein in its needle conformation (98). Contrary to previous models, recent
work by Loquet et al. has revealed that the N-terminus of the needle protein from
Shigella is, in fact, on the outside surface of the needle, exposing it to host
elements, while the conserved carboxy end faces the lumen (63).
How needle length is determined is hypothesized by several models. Models
suggest a ruler method where a specific protein dictates the length of the needle, a
cup method were a specific number of needle proteins are released to create the
needle, or others suggest a combination of these two models with the proteins that
dictate substrate switching also involved in determining needle length (24). Length
of the needle depends on the species of bacteria and studies have shown that this
length is critical in the ability of the bacteria to deliver effectors to the host (24).
Length of the needle is correlated with the length of major features on the outer
surface of the bacteria such as adhesins (72). At the tip of the needle is a protein
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that ‘caps’ the apparatus and interacts with the final portion of the structure that
imbeds in the host membrane (73).
The translocon completes the T3SS. This structure is made up of two
hydrophobic proteins that insert into the host membrane, thus creating a channel
directly from bacteria cytosol into the host cytosol. Through this channel unfolded
proteins can move from the bacteria into the targeted host cell. Some bacterial
species show that these proteins make up the cap structure as well; however this
has not been shown true with all T3SSs (71, 73).

Effectors
Effector molecules can mediate several functions including but not limited
to bacterial uptake, alterations of the immune response, or prevention of
phagocytosis (Figure 2) (39). There are hundreds of different types of effectors
across all T3SS (28). These proteins mimic host cell protein function in order to
irreversibly control specific functions (39). The majority of these proteins carry a
N-terminal secretion signal (23) as well as a chaperone-binding domain to allow
targeting to the T3SS for export (28).
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Figure 2. Cellular effects of T3SS on Shigella, EPEC and EHEC, and Salmonella. (Used with
permission) (16). SopE-like and WxxxE bacterial effectors subvert host cell pathways. Using the
T3SS, Shigella (A), EPEC/EHEC (B), and Salmonella (C) inject the effectors IpgB1/IpgB2,
EspT/Map/EspM, and SopE/SopE2/SifA/SifB, respectively. Except for SifA and SifB, these effectors
activate a cascade of signal transduction pathways, starting with activation of Rho GTPases (either
Rac1, RhoA, or Cdc42), which leads to active polymerization. Membrane ruffles induced by IpgB1,
EspT, SopE, and SopE2 allow bacterial engulfment and subsequent internalization into a bacteriumcontaining vacuole (BCV). Invasive EPEC and Salmonella remain in the BCV and induce the
formation of intracellular actin comets and Salmonella-induced filaments (Sifs), respectively, while
Shigella escapes to the cytosol, where it forms actin tails. In parallel to subversion of actin dynamics,
IpgB1, IpgB2, SopE, and SopE2 induce inflammatory response, EspM, Map, SopE, and SopE2
induce tight junction alteration, and Map induces mitochondrial dysfunction. SopE and SifA, which is
translocated across the SCF via the SPI-2 T3SS, play a role in maintaining the SCF. The activity of
SifB remains unknown.
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Regulation
Regulation of this system is crucial for delivery of effectors at the precise
time needed. Most agree that host cell contact is crucial for activation; however,
how this happens and through which proteins is a major debate in this field (8, 24,
50, 71, 73). Many proteins function to regulate secretion, though the particular
protein and function can vary between different bacterial species. Overall, however,
current theories hypothesize the importance of the needle as a regulatory element
(32). In vivo, contact with the host cell membrane is required to initiate translocation
of effectors (85). One hypothesis of regulation via the needle is that the signal is
structurally relayed via conformational changes of the needle from the tip to the
base. Another hypothesis, separate from needle protein structure, involves a
protofilament, that once released, signals secretion (8). Several mutants of needle
proteins have been produced that alter the regulatory control of secretion; (55, 92,
102) however, an exact mechanism has not been confirmed by analysis of these
mutants.
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Bacteria

Yersinia pestis

History of Plague
Yersinia pestis was separately discovered in 1894 by Alexandre Yersin
and Kitasato Shibasaburō as the causative agent of plague (84). Recognized as
causing the same disease long know to human cultures across the Old World as
“The Plague”, this bacteria became the focus of countless scientists bent on
understanding its power to kill.
Previous to identification, Y. pestis caused three pandemics across the
Old World: The Justinian Plague, The Black Death, and The Third Pandemic.
The Justinian plague was predominantly bubonic and spread via trade routes
from Asia to the Byzantium Empire. The Black Death ravaged the human
populations from China to Europe between the 14th and 19th centuries. All three
forms of the disease (bubonic, pneumonic, and septicemic) appeared during this
pandemic, at times decimating the population by half in major cities. This second
pandemic was so widespread and destructive that it reshaped economies,
science and medicine, art, religion, and society as a whole (60). The Third
Pandemic, predominantly in China, led to the identification of Y. pestis, the
identification of the bacteria’s reservoir: rodent fleas, and the method of spread
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which directed development of control policies for health authorities (60, 84).
This pandemic also brought plague to the United States via shipping routes from
Asia (84).
Currently Yersinia pestis is listed as a category A biological weapon by the
CDC, along with Anthrax, Smallpox, and Tularemia. Category A bacteria are
identified as being easily transmitted from person to person, result in high
mortality, can cause public panic, and require special action for public health
preparedness (CDC). Historically Yersinia pestis has been used as a biological
weapon, by Japan on China. Russia during the Cold war reportedly developed
strains that would be effective terrorism agents; however, these strains were
ordered for destruction (60).

Natural Reservoirs of Yersinia pestis
Yersinia pestis maintains existence in nature by transmission between
susceptible rodents and their fleas, with occasional infection of incidental hosts,
such as humans (84). On a whole the number of human cases worldwide result
in 1,000 to 3,000 deaths per year, with most of those cases occurring in Africa
(Figure 3). The last epidemic of plague was reported in India in 1994 (18). Only
52-100 people died, with mass numbers of antibiotics distributed immediately
and quarantines put into place to limit the spread of disease (18).
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Figure 3. Reported Plague cases by country 2000-2009 (CDC).

Once brought to the United States the bacteria infected the local rodent
population (84). Since then, the bacteria has spread across half of the country
taking up a natural residency in the fleas of rodents such as rock squirrels, the
California ground squirrel, and prairie dogs (18). Human cases are rare (1-15
per year) and only occur in the instance of a human handling or in close contact
with fleas of an infected rodent or direct contact with an infected rodent or feline
(38). Most of these cases are in the southwestern and western areas of the
United States (Figure 4).

Figure 4. Reported cases of human plague – United
States, 1970-2010 (CDC).
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Biovars
Four known biovars of Yersinia pestis exist: medievalis, antigua, and
orientalis and the non-human pathogenic biovar microtus (38, 62, 84, 90). These
biovars are distinguished from each other by their ability to acidify glycerol and
reduce nitrates (38, 84). The biovars were named in accordance to the three
pandemics, however recent analysis of teeth from plague victims links the biovar
orientalis with all three pandemics (90). Y. pestis strains used for the
experiments of this manuscript are derived from the KIM (Kurdistan Iranian Man)
strain and they are of the biovar medievalis.

Transmission of Yersinia pestis
Historically the flea Xenopsylla cheopis, commonly found in association
with rodents, is the major vector of Yersinia pestis (18, 38, 48, 84, 90). Y. pestis
infects fleas by forming a biofilm in the flea’s midgut (48). The biofilm blocks
blood from getting to the flea’s stomach, leaving the flea hungry and also creating
a regurgitation of blood into the host (48). As the flea feeds on its host, the blood
hits the biofilm block picking up bacteria and is regurgitated back into the host,
thus spreading the bacteria to the host (48, 84). This host could be a rodent, in
most cases, or if the opportunity presents itself, a human or other mammal (38).
The still hungry flea will then move on to another site on the same host, creating
multiple sites of infection with the bacteria, or move on to an additional host,
continuing to spread bacteria with each bite (48). Uninfected fleas collect Y.
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pestis by feeding on an infected individual (84). The nature of Y. pestis is to
create a high bacteremia capable of spreading the bacteria back to uninfected
fleas via a blood meal (38, 48). This high bacteremia not only returns the
bacteria into the vector but also kills the host forcing the vector to move to a new
warm body, thus spreading the bacteria to a new host (48, 84).

Disease
Yersinia pestis causes several forms of disease depending upon the route
of entry. The bubonic form of disease is most commonly recognized by the
presence of buboes, i.e. swelling of the lymph nodes with a discoloring of the
enlarged area (84). Other symptoms are characteristically “flu-like”: high fever,
low blood pressure, chills, fatigue, cough, chest pain, and dyspnea (90).
Incubation time of bubonic plague is 2-6 days. The route of entry is commonly an
infected fleabite with bacteria moving to a nearby lymph node via infected
macrophages and then spreading via blood to the liver and spleen (2, 88). In
the blood Y. pestis replicates to high levels causing bacteremia. High levels, >107
CFUs/ml of blood, of bacteria are critical for reinfection of the flea vector (48).
These high bacterial levels however, can lead to septicemic or pneumonic plague
typically resulting in sepsis and death (90). Septicemic plague has similar flu
like characteristics with the addition of organ damage and shock (84).
Pneumonic plague is an infection initiated in the lung by inhaling bacteria
or develops secondary to other infections that have spread to the lung (84). In
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rare cases, pneumonic plague can be transmitted person to person via coughing
droplets of sputum containing bacteria. Incubation time is 1-3 days with a higher
incidence of death then the bubonic form. Symptoms are pneumonia-like with
bloody sputum (90).

Treatment
Upon identification of the disease, the infected individual is isolated and
treatment consists of commonly used broad-spectrum antibiotics (e.g.
tetracycline, streptomycin, or gentamycin) (84). Historically, anyone who
encountered the infected individual would be isolated and any fabric used by the
infected individual would be burned to destroy infected fleas (60).

Vaccines
The CDC offers three routes to control plague: environmental
management, public health education, and preventive drug therapy.
Environmental management can be controlling the local rodent population. Public
health education includes teaching people in plague areas how to limit rodent
populations near their living areas and maintaining flea treatment of pets (84).
Preventive drug therapy is given to an individual who has potentially been
exposed to plague bacteria. Currently there is no approved vaccine for plague in
the United States. Historically, two vaccines were developed and used. One
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involved an attenuated live strain that lacked the pigmentation-locus (Pgm) and
the other was a fully virulent killed strain (84). However, both of these vaccines
had major problems with adverse reactions, no development of long-term
immunity, and they were not able to prevent pneumonic plague (84, 91). Current
vaccine research focuses on development of protein based vaccines involving
the V antigen and the F1 capsule (91).

The Bacteria
Yersinia pestis is a gram negative bacillus that is part of the
Enterobacteriaceae family. The genus Yersinia contains eleven species of
bacteria. Three of these are deemed important for human infection. Yersinia
pestis causes plague. Yersinia pseudotuberculosis and Yersinia enterocolitica
are both enteropathogenic species (84). Y. enterocolitica being the more
common infectious agent of those two, but Yersinia pseudotuberculosis is more
closely related to Yersinia pestis (15). These three species of bacteria share the
T3SS encoding plasmid, called pCD1 in Y. pestis. The extra plasmids Y. pestis
acquired (pPCP1 and pMT1), and loss of several genes created the difference
between an intestinal disease and the terribly lethal plague (15).
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Virulence Factors
Yersinia pestis employs many factors to cause disease; primarily, these
factors are critical for evading detection or suppressing the immune system of the
host. Before entering the host, the bacteria is often found in a flea where several
genes, specifically acquired by Y. pestis as opposed to the other Yersinia
species, are required. Expressed from pMT1, Yersinia murine toxin (Ymt), is part
of the phospholipase D family of proteins and functions in blockage of the flea
gut. Ymt is toxic to mice and causes circulatory failure; however, the protein is
not highly expressed in a bacterial infection of the mouse and plays no known
role in infection of the mammalian host (48). The pgm locus contains the hemin
storage locus (hms). These genes are functional at 28°C (temperature of the flea
vector) and are critical for formation of the biofilm that creates the periventricular
blockage in the midgut of the flea (48). Also encoded from the pgm locus is the
yersiniabactin (Ybt) system that functions in iron uptake. This system is crucial
for survival of the bacteria in low free iron environments (84).
As Y. pestis moves into the human host, the plasminogen activator protein
(Pla) is utilized by the bacteria. This surface protease is expressed from pPCP1
and is responsible for dissemination of the bacteria from the site of fleabites (48,
84). Once disseminated into the host, other bacterial genes become active.
These genes are activated by temperature sensitive regulation elements. Once in
the host the temperature shifts from ambient temperature in the flea to the body
temperature of a mammalian host (84). At this temperature Yersinia pestis
makes a tetra-acylated LPS, instead of a hexa-acylated LPS. Tetra-acylated LPS
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is non stimulatory to Toll-Like Receptor (TLR) 4 and actually antagonizes
hexacylated LPS, consequently reducing innate immune cell activation, cytokine
expression, and maturation of dendritic cells (2). The fraction 1 (F1) capsule,
also only expressed at 37°C from pMT1, forms a gel-like layer around the
bacteria and plays a major role in preventing phagocytosis (84). Yersinia pestis
can survive and replicate in the macrophage, which appears to be critical in
movement through the lymphatic system to the lymph node (2). Known factors
involved in survival in the macrophage are PhoP/PhoQ and a gene located in the
Pgm locus (88). Also at 37°C, the LcrF protein is produced. LcrF is responsible
for the temperature-dependent activation of genes on pCD1 that encodes the
type III secretion system (T3SS) (23). The LcrF transcript has a unique RNA
thermosensor, which once shifted to above 30°C allows for translation to occur
(10). The T3SS in Yersinia pestis then plays a key role in prevention of
phagocytosis, manipulation of cytokine expression, and killing of immune cells
(2). The details of this system are explored separately below.
The attenuated strain of Yersinia pestis used in these studies is the KIM8
strain. This particular strain has a spontaneous deletion of the Pgm locus that
lowers the risk of working with this deadly pathogen. The pPCP1 plasmid has
also been removed to efficiently detect secreted Yops. Pla effectively degrades
secreted proteins (84).
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T3SS
The structure of the T3SS is made up of a basal structure, the needle, and
the translocon. In Yersinia pestis this system is encoded by the pCD1 plasmid.
Also on this plasmid are effectors, chaperones, and regulatory proteins that are
necessary for expression, construction, and expression of the T3S. Without the
T3SS Yersinia pestis becomes avirulent and is easily cleared by the host
immune system (23).
Structure
The base of the T3SS of Yersinia pestis is made up of proteins termed
Ysc (Yop secretion) (Figure 1) (84). The structure is built in the outer membrane
first, made up of YscC, then proceeds to building the inner ring via YscD and
YscJ (30). YscQ reportedly makes up the C-ring on the cytosolic face of the
basal structure (30). YscQ then interacts with the ATPase, YscN, and
subsequently YscN requires YscK and YscL (51). Also essential are integral
membrane proteins YscR, YscS, YscT, YscU and YscV that are thought to
recognize or secrete the Ysc substrates (96).
Extending out from the base is a hollow needle structure, made up of
repeating subunits of YscF. Currently, YscF has only been crystalized in complex
with its chaperones YscE and YscG (99). The pore forming structure at the end of
the needle is called the translocon (12, 67, 73). This structure is made up of
three proteins: LcrV, YopB, and YopD (73). LcrV creates a base on the tip of the
YscF proteins that make up the needle (24) and functions to help insert the
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hydrophobic translocator proteins, YopB and YopD, into the host membrane
(73). YopB and YopD then create a pore and allow Yops to translocate from the
needle apparatus into the host cell (73). In Yersinia there is no evidence for the
order or timing of secretion to assemble the translocon. It is presumed that due
to the hydrophobic nature of YopB and YopD, these proteins are not assembled
at the tip prior to cell contact (74). The translocon as a whole has yet to be
isolated and visualized to confirm this assumption (73). This is contrary to the
T3S system in Shigella where the T3S assembles its major hydrophobic
translocator before cell contact (107). In secretion profiles of Yersinia pestis, in
vitro, all three proteins are secreted into the medium.
Effectors
Effector proteins are the toxins of the T3SS. These proteins, termed Yops
(Yersinia outer proteins) are translocated into the host cell and damage host
responses (Figure 5) (23). Yops have a N-terminal secretion signal (39) and are
translocated in an unfolded state (23).
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Figure 5. Y. pestis resistance mechanisms in opposition to host innate immunity. (Used with
permission) (2). (A) Resistance mechanisms at the early stage of infection. The LPS structure
varieties of Y. pestis during transition between flea and host temperatures make the bacteria
resistant to the serum-mediated lysis and repress the proinflammatory response. In the
meantime, the bacteria phagocytosed by macrophages can grow and express different virulence
determinants to act on host immune response. (B) Resistance mechanisms after the release of
Y. pestis from macrophages. The bacteria released from macrophages attain the capacity to
resist phagocytosis and can inhibit the production of proinflammatory cytokines, which also
attenuate the host’s adaptive immunity.
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YopE, YopT, and YpkA (YopO in Y. enterocolitica) are involved in
preventing phagocytosis by interfering with Rho-GTPases. YopH is a tyrosine
phosphatase that also inhibits phagocytosis. YopH is also involved in
suppressing reactive oxygen species as well as disrupting adhesion proteins.
YopM and YopJ inhibit proinflammatory signaling. YopM has also been
implicated in a global reduction of NK cells. Neutrophil chemotaxis is inhibited by
YopJ (2, 23). YopJ also induces apoptosis of macrophages (59). YopK is known
to regulate the pore size from the host side of the translocon and controls the
rate Yops can enter host cells (29).
Chaperones
Also critical in the regulatory function of the T3SS are chaperone proteins
that are hypothesized to assist in timing and movement of proteins to the
secretion apparatus and/or maintain the protein in an unfolded shape or inactive
state (24). Chaperones are divided into three classes: Class III chaperones
maintain the subunits of the basal structure. Class II chaperones care for the
hydrophobic translocon proteins (24). Specifically in Yersinia pestis, LcrH/SycD
is the chaperone protein for YopD and YopB (76). Along with its chaperone
duties LcrH along with YopD have been implicated in post-transcriptional
regulation of Yop expression (37, 109). Class I chaperones maintain the effector
proteins, although some effectors appear to require no chaperone, e.g. YopM
(24).

	
  

20	
  

Regulation of Secretion
Regulation of the T3SS is a complex process. Under in vivo conditions cell
contact is known to trigger secretion in this system (27). How that signal is
relayed to the inside of the bacteria is not known, although one theory suggests a
conformational change occurs in structural proteins that brings the message to
appropriate regulatory cytoplasmic molecules (8). Under in vitro conditions, the
Yersinia pestis T3S and the Pseudomonas aeruginosa T3S can be triggered by
depleting the media of calcium (11). This response is known as the Low Calcium
Response (LCR). Several proteins are involved in the regulation process of
secretion from inside the bacteria. LcrG blocks secretion that can be alleviated by
interaction with LcrV (44, 66, 77, 95). YopN and YopN’s chaperones SycB and
SycN, along with TyeA, form a complex that also regulates secretion of Yops
(26, 36). YopN regulation is thought to be alleviated by secretion of YopN (44).
Deletion of these regulatory proteins results in an altered ability to secrete Yops.
Either secretion will not occur, such as in the case of deletion of LcrV (6), these
strains are referred to as being calcium independent; or the opposite effect can
occur where secretion will occur constitutively resulting in Yops secretion, for
example a strain lacking LcrG (95) or YopN (36). These strains are called
calcium blind strains. An additional factor that occurs in vitro when secretion is
triggered is a twofold event involving a transcriptional increase in Yops
expression and an overall growth restriction of the bacteria (23).
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Host Response
Once Yersinia pestis has entered the host, via fleabite, the host’s immune
system, likely macrophages and neutrophils, responds to control the infection
(Figure 5) (2). Y. pestis preferentially infects macrophages and is trafficked to
the lymph node where it escapes from macrophages and begins replicating:
disrupting the lymph node, the immune cell population, and possibly spreading to
the blood stream. NK cells and neutrophils, however, have the capacity to kill the
bacteria if they can traffic to the site of infection (2). Mast cells have also been
implicated in resistance to plague although the mechanism is not known (80). At
the site of the bubo, reactive nitrogen species are critical for combating the newly
extracellular bacteria (93). The immune system also attempts to employ TLRs,
the complement system, and the adaptive immune response. However, Y. pestis
is very effective at evading these defenses and shutting down early innate
immune system alarms (2).

Salmonella enterica
Salmonella enterica is a gram-negative pathogen that causes enteric
disease in humans (13, 40). The bacteria are spread by ingestion of contaminated
food, and infection causes diarrhea. There are several serovars of enterica: Typhi
causes Typhoid fever in humans while Typhimurium causes a Typhoid like illness
in mice (13). Once Salmonella has reached the intestine the bacteria attempts to
move across the epithelium layer by invading M-cells (13). This is achieved by the
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use of one of Salmonella’s two T3SS, Salmonella Pathogenicity Island 1 (SPI-1)
(13, 40). SPI-1 plays multiple roles in infection. Initially in infection SPI-1 effectors
cause phagocytosis of the bacteria into epithelial cells and also cause an increase
in inflammatory mediators and fluid movement into the intestine (Figure 2) (40).
The inflammation caused by this system loosens tight junctions in the epithelial
layer, which can allow more bacteria to pass into the lamina propria (13). SPI-1 is
also capable of causing apoptosis of macrophages (40). However, it is also
possible for Salmonella to survive in macrophages. This is accomplished with the
other T3SS of this bacterium SPI-2. Once inside the Salmonella Containing
Vacuole (SCV) SPI-2 effectors protect the bacteria from reactive oxygen and
nitrogen species and orchestrate delivery of materials from the host cell to the SCV
to facilitate bacteria growth (40).
SPI-1 and SPI-2 of Salmonella are found in two families of T3SS. The SPI-1
T3SS is more closely related to the T3SS found in Shigella, while SPI-2 resembles
the E. coli T3SS (24). In our studies, we primarily utilized the needle proteins from
both of these systems: PrgI from SPI-1 and SsaG from SPI-2. Of these two proteins
only PrgI has been crystalized (25).
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Shigella flexneri
Shigella is a genus of gram-negative bacteria of the Enterobacteriacae
family. There are four species: flexneri, sonnei, dysenteriae and boydii. Shigella
flexneri and sonni cause endemic forms of dysentery, while Shigella dysenteriae is
associated with epidemics. These bacteria are spread by contamination of food or
water and only infect humans. Symptoms associated with Shigella range from
moderate to severe diarrhea and in more severe cases fever, abdominal cramps,
and bloody mucoid stools. Death from this pathogen usually results from septic
shock, severe dehydration, or acute renal failure (86).
Once inside the host Shigella targets the colon and moves past the epithelial
layer via M-cells. After crossing the intestinal barrier the bacteria interacts with
macrophages and dendritic cells. This interaction causes an increase in proinflammatory cytokines and chemokines. The increase in inflammation eventually
leads to edema, erythema, abscess formation and musosal hemorrhages (86).
The role of the T3SS in Shigella plays out in invasion of epithelial cells and
macrophages (Figure 2) (55). Effectors not only mediate uptake into the cell but
also begin manipulating the immune response to favor high inflammation (86). Our
studies relating to Shigella’s T3SS focus on the needle protein, MxiH. MxiH has
been crystalized and used to predict the needle structure (7, 27). Mutants of MxiH
indicate that the needle protein plays a role in “sensing” host cell contact and the
triggering of secretion (55).
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Pseudomonas aeruginosa
Pseudomonas aeruginosa is also a gram-negative pathogen that infects
humans. This pathogen is associated with several acute disease types ranging
from pneumonia to infections of the urinary tract, wounds, burns, and
bloodstream. Cystic fibrosis patients are keenly susceptible to Pseudomonas
infections as well.
Like many gram-negative pathogens Pseudomonas also utilizes a T3SS
to manipulate the host. Only four effectors of the T3SS of Pseudomonas exist:
ExoS, ExoT, ExoU, and ExoY. These effectors are capable of preventing
phagocytosis, altering cell trafficking, inhibiting cytokine release, and causing cell
death (46). Ultimately Pseudomonas’ goal is to evade innate immunity (92). The
T3SS of Pseudomonas is closely related to the T3SS of Yersinia and in vitro is
also activated by depletion of calcium in the environment (24). Studies by Broms
et al. have revealed the ability of some Yersinia proteins to substitute for
homologous Pseudomonas proteins; however, the reverse does not always work.
YopD specifically can function in Pseudomonas however PopD, the
Pseudomonas homolog, cannot substitute for YopD, specifically YopD’s
regulatory functions. This study also revealed the importance of translocon
protein chaperones for proper function (14).
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Small Molecule Inhibitors of T3S
The homogeneity of T3S systems between different pathogenic bacteria
has led to the targeting of this system for new drug discovery. The critical role of
T3S systems in disease, and the location of T3S systems on the outside of the
bacteria make it a key feature to exploit to prevent disease (56). Screens for T3S
inhibitors were designed to find compounds that prevented secretion of effectors
but still allowed bacterial growth to decrease evolutionary pressures that can lead
to resistance phenotypes (1, 45, 57, 79, 82, 100). The elimination of a major
virulence factor gives the host immune system an edge over the bacteria,
allowing the host to mount a successful immune response and form effective
immunological memory.
Small molecule inhibitor screens identified compounds that inhibit
functional activity of T3SSs, in the case of effector secretion (5, 45, 57, 79, 82,
106). These compounds must also inhibit at reasonable concentrations and
have low cytotoxicity to be considered for animal use (82). Several compounds
have been identified that prevent secretion and/or translocation (50); however,
how the compounds accomplish this and many of the specific target proteins are
unknown. Some studies were created to target specific proteins of the T3SS.
YopH (33), LcrF (41), and YscN (100) have all been successful targets of such
studies. The ability of these compounds to be effective in species other than
Yersinia has yet to be established.
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Our inhibitor studies utilize a small molecule inhibitor 4-4’ thiobis (2methylphenol) (Compound 2), as identified by Pan et al (83) and an isoform 2,2’thiobis-(4-methylphenol) (Compound D). Compound 2 was found to be effective
at inhibiting secretion of Yersinia as well as Pseudomonas aeruginosa although
no target protein was identified (1, 83).

Host Factors and T3SS
Toll-like receptors are common innate immunity receptors on host cells
(Figure 6). There are several types of receptors and each one traditionally identifies
specific pathogen patterns: TLR1/TLR2 and TLR2/TLR6 work as heterodimers to
recognize lipoproteins, TLR3 recognizes double stranded RNA, TLR4 works in
conjunction with MD-2 and CD-14 to recognize LPS, TLR5 recognizes flagellin,
TLR7 and TLR8 recognize single stranded RNA, and TLR9 interacts with
unmethylated CpG (105). Once binding of the specific substrate occurs many
adaptor proteins contribute to a signaling cascade that leads to activation of
transcription factors, such as NF-kB (54). Activation of NF-kB leads to production
of cytokines and chemokines that can prepare the host immune system to respond
to the pathogen (54). There are two key adaptor proteins that TLRs utilize: MyD88
and TRIF (54). MyD88 is common to all TLRs except TLR3, which uses TRIF
(105). TLR4 is unique that it can use either MyD88 or TRIF as its initial adaptor
protein (54).
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Figure 6. Toll-Like receptors (Used with permission) (54). TLR-mediated immune
responses. TLR2 in concert with TLR1 or TLR6 discriminates between the molecular patterns
of triacyl and diacyl lipopeptide, respectively. TLR3 recognizes dsRNA. TLR4 recognizes
bacterial LPS. TLR7/8 mediates recogniation of imidazoquinolines and ssRNA. TLR9
recognizes CpG DNA of bacteria and viruses. TLR5 recognizes bacterial flagellin and mouse
TLR11 recognizes components of uropathogenic bacteria and profilin-like molecule of the
protozoan parasite Toxoplasma gondii. TLR1/2 and TLR 2/6 utilize MyD88 and TIRAP/MAL as
essential adapters. TLR3 utilizes Trif. TLR4 utilizes four adapters, including MyD88,
TIRAP/MAL, Trif and TRAM. TLR7/8, TLR9, TLR5, and TLR11 use only MyD88. The MyD88dependent pathway controls inflammatory responses, while Trif mainly mediates type I IFN
response. In addition, TLR7/8 and TLR9 induce type I IFN in a MyD88-dependent manner in
pDCs.

Contemporary research directed towards T3S systems largely centers on
the structure, regulation, and role of the translocated toxins in bacterial diseases
(24). Currently few studies are being conducted on the roles of T3S structural
components within the innate immune response such as TLRs. Known TLR
recognized patterns within T3SS include flagellin, the major component of the
bacterial flagellar shaft, known to be an important molecule that interacts with TLR5
and Nlrc4 to induce cytokine expression (70). Homologs of the needle rod protein
PrgJ from Salmonella SPI-1 interact with Nlrc4 to induce cytokines (69).
Interestingly, the equivalent protein of the SPI-2 system, SsaI, does not have the
same effect (69). LcrV at the tip of the needle complex has been reported to
interact with TLR2 (94); however, contradicting reports have called this response
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into question (99). The needle proteins’ location on the outside of the bacteria
appears to be a prime location to activate host TLRs; however, no study has
identified an interaction between host response elements and needle proteins.

The following research was completed to evaluate (1) if an isomer of a
known T3SS small molecule inhibitor (Compound 2) could also inhibit T3SS and if
so by what target and mechanism. (2) What host receptor does full length and
truncated T3SS needle proteins interact with to cause an systemic increase in
cytokines, as seen in previous work by our lab. We demonstrate the successful use
of a novel T3SS inhibitor, Compound D, the target(s) of Compound D with a
proposed mechanism, and the additional characterization of the host innate
immune system response to purified needle proteins of the T3SS. The use of
Compound D has proved to be useful in furthering the understanding of the T3SS.
Characterization of the host innate immune system response to needle proteins will
help to understand how several bacteria manipulate the immune system to cause
disease. This information is useful in creating novel treatments or utilizing current
approved treatments in new ways. Purified needle proteins may also become
useful in artificially modulating the host immune response.
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CHAPTER II
MATERIALS AND METHODS

Bacterial strains and plasmids
Bacterial strains and plasmids used in this study are listed in Table 1. All
strains were stored at -80°C in 25% glycerol (v/v). Electroporation of DNA into Y.
pestis cells was done as described previously (77). Plasmid pBAD YopD was
constructed by cloning a NheI–cleaved PCR product into pBAD18. The primers
used to amplify yopD were 5’YopD BAD NheI (5’ CTC TCT CTC GTT AGC ATG
ACA ATA AAT ATC AAG ACA 3’) and 3’YopD BAD NheI (5’ TCT CTC TCT GCA
TGC TCA GAC AAC ACC AAA AGT GGC 3’). Plasmid pBAD lcrH was
constructed by cloning a SacI and HindIII digested PCR product into pBAD33.
The primers used to amplify lcrH were (5’ CCG AGC TCA GGA GGA AAC GAT
GCA ACA AGA GAC GAC 3’) and (5’ CCC AAG CTT CTG GGT TAT CAA CGC
ACT C 3’). YopE129-Elk expression vector pMH141 was constructed by cloning
an EcoR1 cleaved PCR product into a a SmaI and EcoR1 cleaved pBAD18
vector. The primers used to amplify a YopE-Elk chimera encoding DNA segment
from plasmid pYopE129-Elk {Day 2003} were AraYopEstart (5’ GGA ATT CAG
GAG GAA ACG ATG AAA ATA TCA TCA TTT 3’) and Elk-stop (5’ ACA TGC
TGC TCA CTT GGC CGG GC 3’). Plasmid pMH73 for production of LcrV was
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constructed by cloning a NdeI and BamHI cleaved PCR product into pET9. The
primers used to amplify lcrV were (5’ TAC ATA TGC ATC ATC AT CAT CAT
CAT GTG TTA GAG CCT ACG 3’) and (5’ GCG GGA TCC TCA TTT ACC AGA
CGT GTC ATC TAG C 3’). Plasmid pMH166 for production of YopD were
constructed by cloning a BamHI and NdeI cleaved PCR product into pET9. The
primers used to amplify yopD were YopDStart (5’ GGA ATT CCA TAT GCA TCA
TCA TCA TCA TCA TAC AAT 3’) and YopDstop (5’ GCG GGA TCC TCA GAC
AAC ACC AAA AGC GGC 3’).
Deletion of lcrGVH from KIM8 was accomplished using the method
described by Nilles et al (78). Primers used to create deletion segment: LcrGVs
(5’ CGC GGA TCC GCT ATC TGC TCG AAC AGA 3’) and LcrG 1-5 (5’ CGG
GGT ACC TTA ATG GGA AGA CTT CAT AAT CTA 3’) and lcrH kpnI (5’ TGG
GTA CCT AAG TGG CTT GTT CTT GGC TCA AGA GCT 3’) and lcrHDS (5’
CCA ACG GCG ACT TGT GTT GCC TGT GAT CCT GTA CGG 3’). Upstream
segments were cut with KpnI and BamHI and downstream segments were cut
with KpnI. Segments were ligated in pLD55 after digest with SmaI and BamHI.
Resulting plasmid was used for allele exchange with pCD1 (68).
PCR primers were designed to clone a fragment of yscF missing the 66-bp
region (encoding for the first 22 amino acids) of the N-terminus of YscF into an
expression vector, pET200 (Invitrogen, Carlsbad, CA). The primers used were
TrncYscFStartMT (5’ CAC CCT CAA GAA GCC AGC AGA CGA TGC AAA CAA
AGC GG-3’) and TrnctYscFStopMT (5’- TTA TGG GAA CTT CTG TAG GAT
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GCC TTG CAT TAA-3’). The resulting PCR fragment was cloned into pET200
TOPO® (Invitrogen).
Plasmids used in this study to overexpress needle proteins were
constructed in pET200 TOPO® using ChampionTM TOPO expression kits
(Invitrogen, Carlsbad, CA). Primers for gene amplification were made Eurofins
MWG Operon, Inc (Huntsville, AL). Primers used for cloning were as follows: WT
PrgI forward 5’- CAC CAT GGC AAC ACC TTG GTC-3’, PrgI reverse 5’- TTA
ACG GAA GTT CTG AAT AAT GGC AG-3’, Truncated PrgI forward 5’-CAC CTT
TGA TAC GGG CGT TGA TAA TCT ACA AAC G-3’, WT SsaG forward 5’-CAC
CAT GGA TAT TGC ACA ATT AGT GGA TAG CTC TCC-3’, SsaG reverse 5’TCA GAT TTT AGC AAT GAT TCC ACT AAG CAT ATC C-3’, Truncated SsaG
forward 5’-CAC CCT CTC CCA CAT GGC GCA C-3’. Template DNA for
amplification was generated using the DNeasy kit (Qiagen; Valencia, CA); the
manufacturer’s instructions were followed. PCR was performed using PFU
Turbo® polymerase (Agilent Technologies, Santa Clara, CA). Amplified DNA
was then placed in pET200 using the Champion™ TOPO expression kit,
manufacturer’s instructions were followed. All of the gene constructs were
verified by sequencing by Eurofins MWG Operon (Brussels, Belgium). Vectors
were stored in TOP10 E. coli by chemical transformation. WT and truncated
MxiH encoding plasmids are a kind gift from Dr. William Picking, Oklahoma State
University. Plasmids for protein expression were purified from TOP10 E. coli by
Qiaprep Miniprep kit (Qiagen). Purified plasmid DNA was then transformed into
the expression host, BL21(DE3) Star™ (Invitrogen, Carlsbad, CA).
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Table 1: Strains and Plasmids used in this study
_____________________________________________________________________
Strain

Relevant properties

Reference

Yersinia pestis
+

-

KIM8

pCD1 (Lcr ) pMT1 Pla

S. Straley

KIM8-3002.1

pCD1 ΔyopB [8-388] (Lcr ) pMT1 pPCP1 Sm

KIM8-3002.2

pCD1 ΔyopD [1-305] (Lcr ) pMT1 pPCP1 Sm

KIM8 ΔyopK

pCD1 (Lcr ) pMT1 pPCP1 Sm ΔyopK

KIM D27.1005

pCD1 (Lcr ) pMT1 Sm ΔlcrH

KIM8-3002.9
2002}

pCD1 ΔlcrQ [Δ1−116] (Lcr ) pMT1 pPCP1 Sm

KIM8 ΔyopE

pCD1 ΔyopE [yopE::res, kan::res] (Lcr ) pMT1 pPCP1

KIM8-3002.7

pCD1 ΔlcrG2 [Δ5-95] (Lcr ) pMT1 pPCP1 Sm

KIM8-3002.8

pCD1 ΔlcrGV2 [LcrG Δ6-95] [LcrV Δ1-268] (Lcr ) pMT1

+

-

r

{Skrzypek 1998}

+

-

r

{Williams 1998}

+

-

+

r

Lab Stock

r

{Chen 2011}

+

-

r

(Wulff-Strobel

+

+

-

r

{Nilles 1997}
+

-

pPCP1 Sm

Lab Stock

{Fields 1999}

r
+

-

KIM8 ΔlcrGVH

pCD1 ΔlcrGVH (Lcr ) pMT1 pPCP1

This study

KIM8-3002.N3

pCD1 ΔyopN [48-197] (Lcr ) pMT1 pPCP1 Sm

KIM8 ΔyscB

pCD1 ΔyscB [61-125] (Lcr ) pMT1 pPCP1 Sm

KIM8 3002.P9

pCD1 ΔsycN [34-65] (Lcr ) pMT1 pPCP1 Sm

YP814

pCD1 (ΔsycE-yopE::km yscF D46A) pPCP1 pMT1

G. Plano

-

Novagen

+

-

r

{Hamad 2006}

+

-

r

G. Plano

+

-

r

-

{Day 1998}

E.coli
Novablue

+

recA1 endA1 hsdR17 (rK mk ) supE44 Thi-1 gyrA96
+

+

q

relA1 lac (F’ proA B ) lacI ZΔM15::Tn10)
-

-

-

BL21

F ompT hsdSB (rB mB ) gal dcm (DE3)

Novagen

TOP10

F-mcrA Δ(mrr-hsdRMS-mcrBC) ψ80lacZΔM15 Δlacx74

Invitrogen

nupG recA1 araD139 Δ(ara-leu) 7697 galE15 galK16
R

rpsL(Str ) endA1λ
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Table 1 cont.
Yersinia pseudotuberculosis
+

YP126

Wild type, YPIII(pYV )

{Palmer 1999}

Pseudomonas aeruginosa
PA103

Wild type

{Sato 2011}

Plasmids
r

pBAD18 yopD

araBADp cloning vector, Ap + yopD

This Study

pBAD33 lcrH

araBADp cloning vector, Cm + lcrH

pMH139

araBAD, Ap yopE1-129-Elk

This Study

pMH73

pET9 N-terminus His –LcrV

This Study

pMH166

pET9 N-terminus His –YopD

This Study

r

This Study

r

pET15b MxiH

Bill and Wendy Picking

pET15b Δ1-18 MxiH

Bill and Wendy Picking

pET15b Δ1-17 PrgI

Bill and Wendy Picking

pET200 PrgI

Drew 2012

pET200 SsaG

Drew 2012

pET200 Δ1-9 SsaG

Drew 2012
r

pJM119

pET24b-YscF Km

pMNT67

pET200-trYscF Km

{Matson 2005}
r

Toosky 2011

_____________________________________________________________________

Media and growth conditions
Y. pestis, Y. pseudotuberculosis, P. aeruginosa were grown at 26°C in
Heart Infusion Broth (HIB,Difco, Detroit MI). Overnight cultures were used to
inoculate HIB to an A620 of 0.1 and grown at 26°C with shaking. HIB was
supplemented with 1 mM MgCl2, 2 mM CaCl2 (referred to as cultures with Ca2+)
or supplemented with 2.5 µM EGTA for Ca2+ depletion (referred to as cultures
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without Ca2+). When appropriate, bacteria were grown in the presence of
carbenicillin at a concentration of 50 µg/ml, chloramphenicol at a concentration of
25 µg/ml, and/or arabinose (0.2% w/v) to induce expression of genes [e.g.
truncated yopE-Elk] from the vectors. When the A620 reached 0.2, Compound D
or Compound 2 dissolved in DMSO was added at indicated concentrations. The
cultures were then shifted to 37°C to induce T3S and incubation was continued
for an additional 6 h. Escherichia coli strains were grown at 37°C in LB broth or
on TBA plates with antibiotics added as needed. Antibiotics were used at the
following concentrations: kanamycin, 50 µg/ml, and carbenicillin, 50 µg/ml.

Cell Culture
THP-1 X-Blue Cells were acquired from Invivogen, Town, CA and grown
in RPMI 1640 supplemented with 10% fetal bovine serum, 100 µg/ml Normocin
(Invivogen), 50 µg/ml Pen-Strep (Cellgro, Manassas, VA) at 37°C with 5% CO2.
HEK293 cells expressing human TLR2 (CD14), TLR4 (MD-2/CD14), or TLR5,
were acquired from Invivogen and grown in DMEM supplemented with 4.5 g/l
glucose, 10% fetal bovine serum, 50 µg/ml Pen-Strep, 100 µg/ml Normocin, 2mM
L-glutamine, at 37°C with 5% CO2. THP-1 X-Blue and HEK293 cells contain the
secreted embryonic alkaline phosphatase (SEAP) reporter gene under control of
NF-κB and AP-1 (THP-1 X-Blue) or NF-κB (HEK293).
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His-tagged Protein Isolation
Escherichia coli BL-21(DE3) carrying plasmids for a given protein were
grown overnight in non-inducing media (50xM, 1M MgSO4, 40% glucose, 5%
Aspartic Acid, (97)) supplemented with the correct antibiotic. Bacteria were then
inoculated into auto-inducing media (50xM, 1M MgSO4, 50x5052, NZ-amine S,
Yeast Extract, distilled water, (97)) with antibiotic and grown to an A620 of 0.60.8. Cells were harvested by centrifugation at 4,000 x g for 10 min at 4°C and
resuspended on ice in wash buffer (50 mM NaH2PO4, 300 mM NaCl, 10% (w/v)
glycerol). The resulting cellular suspension was then French pressed at 20,000
psi twice to lyse cells. The lysate was then clarified by centrifugation at 4,000 x g
for 20 min. The clarified supernatant was collected and diluted with 1,000 mL of
wash buffer before application to pre-equilibrated TALON metal affinity resin
(Clontech, Mountain View, CA) column. The lysates were applied to the columns
twice before washing with new wash buffer. Bound protein was eluted in buffer
containing 50 mM sodium phosphate, 200 mM NaCl, 150 mM imidazole, and
20% glycerol (w/v). Purified protein was concentrated with Amicon Ultra
Centrifugal Filters (Millipore, Billerica, MA) and dialyzed against PBS + 10%
glycerol (w/v) in Slide-A-Lyzer dialysis cassettes (Thermo Fisher Scientific,
Rockford, IL) before SDS/Page gel assessment of purity. Protein concentrations
were determined by Bradford Protein Assay Kit (Thermo Fisher Scientific,
Chicago, IL) and stored at -20°C for future use.
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Secreted protein sample preparation
After 4 h of growth at 37°C in HIB, samples from Y. pestis cultures were
taken for analysis of Yops secretion and expression. Whole cells were separated
from cell-free culture supernatants by centrifugation for 5 minutes at 16400 g and
4°C as previously described (77). Proteins were precipitated from whole cell or
culture supernatant fractions with 10% trichloroacetic acid (w/v, TCA), and
subsequently dissolved at 0.1 A620•ml in 2x SDS-PAGE sample buffer (77).

Protein electrophoresis and immunoblot detection
Whole cell and supernatant protein samples were used to load single
lanes for SDS—polyacrylamide gel electrophoresis (SDS-PAGE) according to
the method described by Laemmli (58). Samples were boiled for 10 minutes
before loading on gels. Proteins separated by SDS-PAGE were then transferred
to Immobilon-P membrane (Millipore Corp., Bedford, Mass) for immunoblot
analysis of select proteins (LcrV, YopB, YopD, YopE, YopM, YopN, YopK, Elk)
using polyclonal antibodies specific for each Yop (His-tagged LcrV (αHTV) (77),
YopM (αYopM) (75), YopN (also known as LcrE (αLcrE) (77), YopE (α-YopE;
gift from S.C. Straley, University of Kentucky, Lexington), and YopB (α-YopB; gift
from J.B. Biliska, Stony Brook University, Stony Brook, New York), YopK (αYopK – Lab Stock), or a monoclonal for Elk (Cell Signaling, Beverly MA). Bound
primary antibodies were detected with alkaline phosphatase conjugated to
secondary antibodies (goat anti-rabbit immunoglobulin G; Pierce) followed by
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color development with 5-bromo-4-chloro-3-indolylphosphate/nitroblue
tetrazolium (NBT-BCIP, Thermo Fisher Scientific, Chicago, IL).

Hemolysis Assay
Yersinia pestis deleted for yopK was grown overnight in BHI. The bacteria
was then subcultured to an A620 of 0.3 and supplemented with EGTA. After
growing for 1 h temperature was shifted to 37°C and grown for 3 h. Bacteria were
then resuspended in 37°C PBS to a density of 50 A620•ml. Sheep Blood was
centrifuged at 1,000 x g for 10 min at room temperature, washed twice in ice-cold
PBS, and resuspended to 4x109 cells/ml. In 96 well plates, 50 µl of RBC’s with 50
µl of bacteria were combined and some samples were treated with 60 µM of
Compound D as indicated. The plate was then centrifuged at 1,000 x g at room
temperature for 10 min. The plate was then moved to 37°C for 3.5 h. After the
incubation 150 µl of PBS was added to wells (water was added to one set of cells
as a control for RBC lysis) and the plate was again centrifuged at 1,000 x g at
4°C for 10 min. 100 µl of supernatant was transferred to a clean plate and the
A570 read.

His-tagged Proteins interaction with Compound D
HisPur Cobalt Resin (Thermo Fisher Scientific) was mixed overnight at
4°C with PBS or His6-LcrV or His6-YopD. Resin/Protein mixture was eluted by
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centrifugation at 700 g at 4°C. Compound D or Compound 2 dissolved in DMSO
or DMSO alone was added to remaining resin and mixed overnight at 4°C.
Compound D, Compound 2 or DMSO were eluted the next morning and added to
flasks containing Y. pestis KIM8 to assess presence of inhibitor by the ability of
the elute to effect the ability of Y. pestis KIM8 to secrete Yops.

Stimulation of SEAP activity in cell lines by needle proteins
THP-1 X-Blue cells were seeded at 2 x 106 cells/ml and HEK 293 cells at
2.5 x 105 cells/ml. Cells were suspended in infection medium as described by the
manufacturer. Proteins were added at a final concentration of 1 µg/mL. As
indicated, 20 µg/ml of antibodies (PAb (polyclonal antibody) Control, PAb hTLR2,
Invivogen) or TLR4 inhibitor CL1-095 (Invivogen) were added to cell cultures, as
suggested by the manufacturer, prior to addition of needle proteins. Cells were
stimulated at 37°C with 5% CO2 for 5 h or 24 h, as indicated.

Enzyme Digestion of Needle Proteins
Proteinase K (Thermo-Fisher) 40 µg/ml was used to digest needle
proteins and flagellin. PBS treated with proteinase K was used as a control.
Proteins were digested overnight at 37°C. Proteinase K was then inactivated with
1.6 mg/mL phenylmethanesulfonylfluoride (PMSF). Digested proteins and PBS
treated were then used to stimulate THP-1 cells.
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LPS Assay
ToxinSensor Chromogenic LAL Endotoxin Assay Kit (GenScript,
Piscataway NJ) was used to test for endotoxin in protein samples. The Kit was
used as described by the manufacturer. An equivalent amount of the endotoxin
standard as found contaminating the needle protein samples was then applied to
THP-1 X-Blue cells as described above, resulting in no stimulation of THP-1 XBlue cells.

Cytokine Analysis
Cellular supernatants from THP-1 X-Blue NF-kB activation experiments
were collected and stored at -80°C before analysis with Quantikine Elisa kits from
R&D Systems (Minneapolis, Minnesota). The Human TNF-α kit was used as
instructed by manufacturer.

SEAP Reporter Assays
Quantification of secreted embryonic alkaline phosphatase (SEAP) from
the supernatant was detected using Quanti-Blue reagent (Invivogen) according to
manufacturer’s protocol. A microplate reader, Synergy HT (Bio-Tek, New
England Ipswich, MA) quantified SEAP at 630 nm using KC4 v3.3 software (BioTek).
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Image acquisition and production
All immunoblots were scanned on Epson 4490 Perfection scanner at 4800
dpi using VueScan Software (v. 8.4.40; Hamrick Software,
[http://www.hamrick.com]. The scanned blots were imported into Adobe
Photoshop [CS5.1, Adobe Software, San Jose, CA) the images were converted
to grayscale and the autolevels function was applied. Final figures were
assembled in Adobe Illustrator (CS5.1) and images were downscaled to the final
resolution upon export to the PNG file format.

Data Analysis and Statistics
Needle Protein data was assembled into graphs using GraphPad Prism,
version 5.0d (GraphPad Software). Statistical analysis of SEAP levels was
completed by using one way analysis of variance with Bonniferri or Dunnett’s
Multiple Comparisons posttest.
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CHAPTER III
RESULTS

Results inhibitor Compound D

Compound D inhibits secretion of Yops by Kim8
Several T3SS inhibitors have been identified, including an isoform of
Compound D (Figure 7) (83). We intended to evaluate the ability and
mechanism of Compound D to inhibit T3SS in Yersinia pestis. Compound D was
found to inhibit secretion of YopB, YopD, YopK, YopM, and YopE at a
concentration of 60 µM (Figure 8A lane 4) in Y. pestis KIM8. Interestingly, LcrV
secretion was not inhibited, suggesting functional needles were assembled,
implying that Compound D functioned after secretion of LcrV was initiated. Whole
cell fractions demonstrated the presence of YopB, YopD, YopK, YopM, and
YopE proteins by immunoblotting (Figure 8B) within bacteria. Expression of the
analyzed proteins appeared to remain at lower levels, indicative of a nonsecreting environment (Figure 8B lane 4) (85). At 20 µM Compound D low levels
of Yops secretion were seen in supernatant samples and cellular levels were
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more comparable to wildtype in the absence of calcium (Figure 8A-B lane 6).
Compound D, like its isomer Compound 2, was found to be toxic to cultured
eukaryotic cells (data not shown), resulting in an inability to examine the ability of
Compound D to inhibit Yops translocation into cultured cells. An alternative
method to evaluate translocation is to examine the ability of Y. pestis yopK
strains to lyse red blood cells (47, 77). In order to test the effect of Compound D
on Yops translocation into red blood cells, we tested the yopK strain with
Compound D. Compound D was able to inhibit secretion of YopM and YopE just
as seen with the wildtype (Figure 9A) with similar effects compared to wildtype on
cellular protein levels (Figure 9B). Once the effect of Compound on the yopK
strain was determined to inhibit Yops secretion like the wildtype strain, an
attempt to analyze the effect of Compound D on translocation was performed
using a hemolysis assay. yopK strains will lyse red blood cells as an indicator of
active translocation (47, 77). However, Compound D lysed red blood cells (data
not shown) making the effect of Compound D on translocation impossible to
evaluate. Subsequently all studies analyze Yops secretion into the culture
medium.

Figure 7. Compound D
2,2’-thiobis-(4-methylphenol) structure
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B.

Figure 8. Compound D inhibits secretion in wildtype Yersinia pestis KIM8
(A) Secreted and (B) Cellular proteins from Y. pestis KIM8 assessed via immunoblot with antibodies to
YopM, YopB, LcrV, YopD, YopE, and YopK in the absence of Compound D (lanes 1-2) and presence
of Compound D at 60µM (lanes 3-4), 20µM (lanes 5-6). For panels A and B odd numbered lanes are
samples in the presence of calcium and even numbered lanes are samples in the absence of calcium.
All lanes are loaded with protein derived from 0.05 A620•ml of bacterial culture.

Figure 9. Compound D inhibits secretion in a Y. pestis ΔyopK strain
(A) Secreted and (B) Cellular proteins in Y. pestis KIM8 ΔyopK were assessed via
immunoblots probed with antibodies to YopM and YopE. Samples lacking Compound D
(lanes 1-2) and treated with 60µM Compound D (lanes 3-4). For panels A and B odd
numbered lanes are samples in the presence of calcium and even numbered lanes are
samples in the absence of calcium. All lanes are loaded with protein derived from 0.05
A620•ml of bacterial culture.
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Translocon protein YopD plays a role in Inhibition of Secretion by
Compound D
Since secretion of the translocon-staging protein LcrV was unaffected by
Compound D, strains lacking the other translocon proteins YopD and YopB were
evaluated for the ability of Compound D to inhibit Yops secretion. The Y. pestis
yopB strain behaved similar to wildtype Y. pestis (Figure 10A and 10B): In the
presence of Compound D, Yops were present in whole cell fractions although at
low levels, indicative of a non-secreting environment, and Yops were not
secreted under secretion permissive circumstances. However, when the yopD
mutant was grown under secretion inducing conditions in the presence of
Compound D, Yops secretion was not inhibited as seen in the wildtype strain and
the yopB strain (Figure 10C lanes 4 and 6), suggesting that YopD plays a role in
inhibition mediated by Compound D. As expected, hyper secretion of Yops was
seen in the cellular environment of the ΔyopD strain and the levels of cellular
proteins were not affected by the inhibitor (Figure 10D). This result suggests
YopD is involved in Compound D inhibition; however, YopB is not.

LcrH and LcrQ uniquely affect Compound D inhibition
Since both YopB and YopD require the chaperone LcrH (SycD) for
function, the effect of Compound D on an lcrH deleted strain was examined. As
shown by Francis et al., phenotypically distinguishing between an lcrH deleted
and yopD deleted strain is difficult (37). The phenotypic effects of deleting lcrH
could have to do with lacking YopD or YopB and not LcrH. Therefore, the lack of
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Figure 10. Compound D blocks secretion in a Y. pestis yopB strain, but not in a Y. pestis
yopD strain.
(A) Secreted and (B) cellular proteins from Y. pestis KIM8 ΔyopB were assessed via
immunoblots probed with antibodies to LcrV, YopN and YopE in the absence (lanes 12) and the presence of 60 µM Compound D (lanes 3-4). (C) Secreted and (D) cellular
proteins from Y. pestis KIM8 ΔyopD were assessed via immunoblots probed with
antibodies to YopN and YopE in the absence (lanes 1-2) and presence of Compound
D at 80 µM (lanes 3-4), 60 µM (lanes 5-6), and 20 µM (lanes 7-8). For panels A-D odd
numbered lanes are samples in the presence of calcium and even numbered lanes
are samples in the absence of calcium. All lanes are loaded with protein derived from
0.05 A620•ml of bacterial culture.
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secretion inhibition in the yopD strain could be due to effects on either LcrH or
YopD. Hence, an lcrH strain was tested with Compound D. lcrH strains hyper
secrete Yops just as yopD strains (Figure 11B). When Yops secretion in the lcrH
strain was examined in the presence of Compound D, YopE secretion was
inhibited, while YopM secretion was not inhibited (Figure 11A lane 4).
Interestingly, YopE has a chaperone protein, while YopM does not. This tells us
that LcrH could be involved with Compound D; or a function of LcrH on YopD
may be to affect the secretion of unchaperoned Yops such as YopM.

Ca2+

Ca2+

Figure 11. Compound D inhibits secretion of YopE but not YopM in a Y. pestis lcrH strain
(A) Secreted and (B) Cellular proteins from Y. pestis KIM5 ΔlcrH were assessed via
immunoblots probed with antibodies to YopM and YopE in the absence (lanes 1-2) and the
presence of 60µM Compound D (lanes 3-4). For panels A-D odd numbered lanes are samples
in the presence of calcium and even numbered lanes are samples in the absence of calcium.
All lanes are loaded with protein derived from 0.05 A620•ml of bacterial culture.
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LcrQ function relies upon YopD (109) and is thought to regulate the
hierarchy of Yops secretion (110). We therefore also looked at an lcrQ deleted
strain. Yop secretion is normal in the absence of Compound D. When the lcrQ
strain is grown in the presence of Compound D, YopM and YopE secretion are
reduced but not eliminated, and the effect appears to be greater on YopE (Figure
12A, lane 4). This result indicates that LcrQ or its function at the sorting complex
could play a role in inhibition by Compound D. Expression of YopM and YopE
appears to be reduced in the presence of the inhibitor, as seen by the reduction
of levels evident by immunoblotting whole cell fractions (Figure 12B).

Ca2+

Ca2+

Figure 12. Compound D also inhibits secretion of YopE but not YopM in a Y. pestis
ΔlcrQ strain.
(A) Secreted and (B) cellular proteins from Y. pestis KIM8 ΔlcrQ were assessed
via immunoblot probed with antibodies to YopM and YopE in the absence
(lanes 1-2) and the presence of 60µM Compound D (lanes 3-4). For panels A
and B odd numbered lanes are samples in the presence of calcium and even
numbered lanes are samples in the absence of calcium. All lanes are loaded
with protein derived from 0.05 A620•ml of bacterial culture.
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Overexpression of YopD in KIM8 overcomes Compound D inhibition
To confirm involvement of YopD with Compound D, YopD was
overexpressed in trans in Y. pestis strain KIM8 (Figure 13A and 13B). If YopD is
the target of Compound D than overexpression of YopD might relieve the effect
of Compound D. However, overexpression of YopD alone did not alleviate
Compound D’s ability to inhibit secretion (Figure 13A, lanes 5-8). Since
overexpression of YopD alone did not alleviate the effect of Compound D in
KIM8, both YopD and its chaperone LcrH were overexpressed and tested for the
relief of Compound D-mediated inhibition of Yops secretion. Overexpression of
YopD and LcrH overcame the inhibitory effect of Compound D (Figure 13A: lanes
13-16) in KIM8. Overexpression of LcrH alone resulted in reduced secretion and
cellular expression without Compound D as previously observed, (6) and no
secretion in the presence of Compound D (Figure 13A: lanes 9-12). By
overexpressing YopD and LcrH, the inhibitory effect of Compound D was
alleviated, indicating the extra YopD and/or LcrH sequestered the inhibitor and
allowed secretion to occur.

YopD and LcrH transcomplement a YopD mutant to restore inhibition by
Compound D
The ΔyopD mutant was complemented with plasmids containing yopD,
lcrH, or with yopD and lcrH (Figures 14A and 8B). Again, expression of yopD or
lcrH alone in the ΔyopD strain did not restore the ability of Compound D to inhibit
secretion (Figure 14A, lanes 5-12). Expression of yopD did reduce the hyper-
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Figure 13. Overexpression of YopD and LcrH in wildtype overcomes Compound D
(A). Secreted and (B) cellular proteins from Y. pestis KIM8 with overexpressed yopD, lcrH, or yopD
and lcrH were assessed via immunoblot with antibodies to YopM and YopE in the absence (lanes 12, 5-6, 9-10, and 13-14) and presence of 60 µM Compound D (lanes 3-4, 7-8, 11-12, 15-16). For
panels A and B odd numbered lanes are samples in the presence of calcium and even numbered
lanes are samples in the absence of calcium. All lanes are loaded with protein derived from 0.05
A620•ml of bacterial culture.	
  

expression of YopM and YopE in the ΔyopD strain (Figure 14B, lanes 5-8),
indicating a restoration of YopD’s regulatory role yet hyper secretion of Yops was
still seen (Figure 14A, lanes 5-8). Interestingly, overexpression of LcrH in a yopD
strain resulted in a dramatic reduction in cellular expression of YopM and YopE
(Figure 14B, lanes 9-11), with no secretion occurring with or without the inhibitor
present (Figure 14A, lanes 9-11). Co-expression of yopD and lcrH resulted in
complementation to restore the ability of Compound D to inhibit secretion (Figure
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14A, lanes 13-16). These results suggest that YopD or the YopD/LcrH complex
are involved in inhibition by Compound D.

Figure 14. Transcomplementation of Y. pestis ΔyopD with YopD and LcrH restores
Compound D’s ability to inhibit secretion.
(A). Secreted and (B) cellular proteins from Y. pestis KIM8 ΔyopD complemented
with yopD, lcrH, or yopD and lcrH were assessed via immunoblot with antibodies to
YopM and YopE in the absence of Compound D (lanes 1-2, 5-6, 9-10, and 13-14)
and presence of 60 µM Compound D (lanes 3-4, 7-8, 11-12, 15-16). For panels A
and B odd numbered lanes are samples in the presence of calcium and even
numbered lanes are samples in the absence of calcium. All lanes are loaded with
protein derived from 0.05 A620•ml of bacterial culture.
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Interaction of YopD with Compound D
In order to evaluate if Compound D was interacting with YopD, His-tagged
YopD or His-tagged LcrV in PBS or PBS alone was administered to a cobaltimmobilized metal affinity chromatography (IMAC) resin to retain poly-histidine
tagged YopD on the resin columns. After washing the columns, DMSO alone,
Compound D or Compound 2 dissolved in DMSO was added to the columns.
The flow through was collected and added to Y. pestis KIM8 cultures to test if the
inhibitor was present and able to inhibit secretion. Y. pestis KIM8 was grown and
treated with Compound D that was not gel-treated as a control. Cellular proteins
were all comparable (Figure 15B). The flow through from a PBS-only treated
column with Compound D added was able to inhibit secretion of YopE and
reduced secretion of YopM, indicating the inhibitor was able to pass through the
column and not interact with the gel resin (Figure 15A, lanes 5-6). When the
column was treated with his-tagged LcrV as a negative control, the inhibitor was
still able to pass through and inhibit secretion as expected, showing that LcrV
does not bind Compound D (Figure 15A, lanes 7-8) and that Compound D is not
simply absorbed by protein. As a control a his-tagged YopD-loaded column had
DMSO alone applied and the flow through was not able to inhibit secretion
(Figure 15A, lanes 9-10). When Compound D and Compound 2 were
administered to a his-tagged YopD-loaded column and added to KIM8 cultures,
the flow-through from the Compound 2-treated column was able to inhibit
secretion (Figure 15A, lanes 13-14). However, the flow-through from the
Compound D-treated column was unable to inhibit secretion, suggesting that
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Compound D was no longer present to inhibit secretion (Figure 15A, lanes 1112), denoting that Compound D was retained on the his-tagged YopD-treated
column. This result suggested that his-tagged YopD was able to interact with
Compound D and Compound D was removed from the DMSO solution. In
contrast, the related chemical Compound 2 was not retained under the same
conditions suggesting the retention of Compound D is a specific interaction.
These results indicated that Compound D is capable of binding to YopD.

Ca2+

Ca2+

Figure 15. Compound D is pulled out of solution when exposed to YopD.
Recombinant proteins, His6-YopD (lanes 9-14) or His6-LcrV (lanes 7-8), or PBS (lanes 5-6) were
combined with Talon affinity gel and Compound D (lanes 7-8 and 11-12) or Compound 2 (lanes 13-14)
or DMSO (lanes 9-10) were exposed to gel/protein combinations. Flow through was then used to
evaluate (A) secreted and (B) cellular protein of wildtype strain KIM8 to determine the presence of the
inhibitors. Evaluation was done via immunoblot using antibodies to YopM and YopE. Control protein
analysis was done in the absence of Compound D (lanes 1-2) and presence of 60 µM Compound D
(lanes 3-4). For panels A and B odd numbered lanes are samples in the presence of calcium and even
numbered lanes are samples in the absence of calcium. All lanes are loaded with protein derived from
0.05 A620•ml of bacterial culture.	
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Secretion of YopE expressed from a non-native promoter is inhibited by
Compound D
A yopE strain retained the ability of Compound D to inhibit Yops secretion
indicating that YopE is not involved with Compound D’s ability to inhibit Yops
secretion. YopM and YopN secretion was still inhibited by Compound D in a
yopE strain (Figure 16A). Since YopE was not involved in Compound D
inhibition, a truncated YopE-Elk chimera expressed under a non-native promoter
(araBADp) was used to analyze whether Compound D was acting at the level of
secretion or expression of Yops. The YopE-Elk chimera was secreted in media
lacking calcium as expected (Figure 16B: lane 2). However, in the presence of
Compound D secretion of the YopE-Elk chimera was inhibited along with the
natively expressed Yops (Figure 16B: lane 4), indicating inhibition of secretion is
not tied to regulation of gene expression within the T3SS.

Regulatory differences in strains with unregulated Yops secretion by
Compound D
Strains of Y. pestis with certain T3SS regulatory proteins deleted have the
ability to secrete Yops despite the presence of calcium. These strains
constitutively secrete Yops and are referred to as ‘calcium blind’ strains. Two
sets of regulatory calcium blind strains representing two distinct regulatory
pathways were tested in the presence of Compound D: strains with deletions of
lcrG, or lcrG and lcrV (Figure 17A-D) and strains with deletions of yopN, yscB, or
sycN (Figure 18A-F). For the strains lacking LcrG or LcrG and LcrV, secretion of
Yops was inhibited in the secretion inducing environment of all tested strains.
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Ca2+

Figure 16. Compound D’s inhibits secretion of a YopE-Elk Chimera
(A) Secreted proteins from Y. pestis KIM8 ΔyopE were assessed via immunoblots
probed with antibodies to YopM and YopN in the absence (lanes 1-2) and presence
of Compound D at 80 µM (lanes 3-4), 60 µM (lanes 5-6), and 20 µM (lanes 7-8). (B)
Secretion and (C) Cellular proteins from Y. pestis KIM8/pYopE129-Elk were assessed
via immunoblots probed with antibodies to LcrV, YopE, and Elk in the absence (lanes
1-2) and presence of Compound D at 60 µM (lanes 3-4). For panels A-C odd
numbered lanes are samples in the presence of calcium and even numbered lanes
are samples in the absence of calcium. All lanes are loaded with protein derived from
0.05 A620•ml of bacterial culture.
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Figure 17. Compound D does not block secretion in the presence of Ca
ΔlcrGV strain

2+

in Y. pestis ΔlcrG or

(A and C) Secreted and (B and D) cellular proteins from regulatory mutants: ΔlcrG (A-B) and
ΔlcrGV (C-D) were assessed via immunoblots probed with antibodies to YopE and/or YopN in
the absence (lanes 1-2) and presence of Compound D at 60 µM (lanes 3-4). For panels A-D
odd numbered lanes are samples in the presence of calcium and even numbered lanes are
samples in the absence of calcium. All lanes are loaded with protein derived from 0.05 A620•ml
of bacterial culture.

However, secretion of Yops in the presence of calcium was not inhibited,
indicating a difference in the regulation of the T3SS between the two
environments. In the strains lacking YopN and its chaperones, YscB and SycN, a
similar pattern was seen: secretion in the presence of calcium was not affected
by Compound D. However, in the absence of calcium, YopM and YopE secretion
was greatly reduced in the ΔyopN and ΔyscB strains (Figure 18A and 18C), or
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completely absent in the ΔsycN strain (Figure 18E). Cellular levels of Yops were
comparable in all strains, with a slight reduction in the non-secreting conditions.
The ability of Compound D to inhibit secretion in the absence of calcium but not
the presence could indicate an interaction with calcium or that a change in the
T3SS structure in the absence of calcium allows the inhibitor to cause the effect
of blocking secretion.

Constitutive secreting yscF mutant inhibited in presence and absence of
calcium
Torruellas et al. identified YscF mutants that constitutively secrete Yops
(102). We used a pPCP1- derivative of KIM5-3001.P61 +pYscF (D46A) (102),
YP814, a strain that has YscF (D46A) expressed in cis on pCD1. YP814 was
grown with Compound D to see the effect compared to the previous constitutively
secreting strains. In the case of YscF D46A, Compound D was able to inhibit
secretion of YopE in both the presence and absence of calcium (Figure 19, lanes
3 and 4) contrary to what we had seen in in Figures 17 and 18. The result of
blocking secretion in the presence of calcium shows that Compound D activity is
not affected by calcium. This specific mutant, expressing an altered needle,
allowed Compound D to inhibit secretion in both the presence or absence of
calcium. These data indicate that a certain needle conformation may be required
for Compound D to inhibit secretion.
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Figure 18. Compound D does not block secretion in the presence of Ca

2+

-

in YopN strains

(A,C,E) Secreted and (B,D,F) cellular proteins from regulatory mutants: Y. pestis ΔyopN
(A-B), ΔyscB (C-D), and ΔsycN (E-F) were assessed via immunoblots probed with
antibodies to YopE and YopM in the absence (lanes 1-2) and presence of Compound D
at 60 µM (lanes 3-4). For panels A-F odd numbered lanes are samples in the presence
of calcium and even numbered lanes are samples in the absence of calcium. All lanes
are loaded with protein derived from 0.05 A620•ml of bacterial culture.
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Figure 19. Yops secretion in a Y. pestis YscF D46A strain is inhibited by Compound D.
(A) Secreted and (B) cellular proteins from Y. pestis YP814, a strain expressing YscF
D46A were assessed via immunoblots probed with antibodies to LcrV, YopD, and YopE
in the absence (lanes 1-2) and presence of Compound D at 60 µM (lanes 3-4). For
panels A and B odd numbered lanes are samples in the presence of calcium and even
numbered lanes are samples in the absence of calcium. All lanes are loaded with
protein derived from 0.05 A620•ml of bacterial culture.

Compound 2 role in inhibiting secretion is different than Compound D
The related inhibitor, 4,4’-thiobis(3-methylphenol) (Compound 2) (Figure
20A), discovered by Pan et al. (82) was assessed in comparison to Compound
D. Both compounds effectively inhibit secretion of Yops (Figure 20B). However
where removing YopD can alleviate Compound D’s effect, Compound 2 is
unaffected (Figure 20C: lanes 1-4). YopD does not play a role in Compound 2’s
mechanism to inhibit secretion. YopB was also evaluated with Compound 2 and
again secretion was inhibited indicating YopB is not involved (Figure20C: lanes
5-8). A constitutive Yops secreting strain lacking LcrG and LcrV was tested to
see if Compound 2 was only inhibited in the absence of calcium as well.
Compound 2 was able to inhibit secretion in both the presence and absence of
calcium, contrary to the effect of Compound D on calcium blind strains
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(Figure20D). Therefore Compound D and its isomer Compound 2, although both
inhibitors of type III secretion, are accomplishing inhibition of secretion in different
ways.
A.	
  

Figure 20. Compound 2 an isomer of Compound D
does not target YopD.
(A).Compound 2 4-4’ thiobis (2-methylphenol) structure.
(B) Wildtype KIM8 was grown in the absence (lanes 1-2)
and presence (3-4) of 60 µM Compound 2. Secretion
was evaluated by immunoblot with antibodies to YopM,
LcrV and YopE. (C) Translocon mutants YopD and
YopB were grown in the absence (lanes 1-2, 5-6) and
presence (3-4, 7-8) of 60 µM Compound 2 and
evaluated for Yop secretion via immunoblot to
antibodies of LcrV and YopE. (D) Calcium blind mutant
LcrGV was also grown up in the absence (lanes 1-2)
and presence (3-4) of 60 µM Compound 2 and
evaluated for Yop M and YopE secretion via
immunoblot. For panels B-D odd numbered lanes are
samples in the presence of calcium and even numbered
lanes are samples in the absence of calcium. All lanes
are loaded with protein derived from 0.05 A620•ml of
bacterial culture.
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Effects of Compound D on Pseudomonas aeruginosa and Yersinia
pseudotuberculosis
Compound D’s ability to affect secretion in Pseudomonas aeruginosa and
Yersinia pseudotuberculosis (Figure 21A and B) was also evaluated. In both
cases Compound D was able to reduce the level of secretion. Given that the two
bacteria have increased growth rates compared to Yersinia pestis, it was not
surprising that the same concentration that was proficient at completely inhibiting
secretion in Yersinia pestis was not sufficient to inhibit secretion in Pseudomonas
aeruginosa and Yersinia pseudotuberculosis. However, effector secretion levels
were definitely affected by the presence of Compound D, indicating this
compound is effective against other related T3SS.

Figure 21. Compound D decreases effector
secretion from P. aeruginosa and Y.
pseudotuberculosis.
(A) Secreted proteins from Yersinia
pseudotuberculosis grown in the
absence (lane 1-2) and presence (lanes
3-4) of 60 uM Compound D were
evaluated by immunoblot for YopE. (B)
Secreted proteins from Pseudomonas
aeruginosa at 2 hours (lanes 1-4) and 4
hours (lanes 5-8) were grown up in the
absence (lanes 1-2, 5-6) and presence
(lane 3-4 and 7-8) of 60 uM Compound
D. Proteins were evaluated by
immunoblot for ExoU and PopD. For
panels A and B odd numbered lanes are
samples in the presence of calcium and
even numbered lanes are samples in the
absence of calcium. All lanes are loaded
with protein derived from 0.05 A620•ml of
bacterial culture.
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Results of Needle Protein Activation of Host Cells

Alignment of Needle proteins
Type III secretion systems found in animal pathogens can be divided up
into three main families: Ysc injectisomes (e.g. Yersinia spp and Pseudomonas),
Shigella and Salmonella SPI-1 type injectisomes, and injectisomes like the
systems found in E. coli and Salmonella SPI-2 (24). Our assessment of needle
proteins includes at least one needle protein homolog from each T3SS family
from bacteria that are human pathogens, as well as representing both
Salmonella injectisomes: needle proteins from Yersinia pestis (YscF), Salmonella
enterica serovar Typhimurium SPI-1 (PrgI), SPI-2 (SsaG), and Shigella flexneri
(MxiH). Needle proteins of T3SS are highly conserved, except for the N-termini
(Figure 22). Selected protein sequences were aligned and truncated forms of
these proteins were made by deleting the N-termini corresponding to the twentysecond amino acid from the N-terminus of Yersinia pestis YscF. This
corresponded to an 18 aa truncation of PrgI, a 15 aa truncation of MxiH, and a 9
aa truncation of SsaG, which is already naturally truncated in relation to the other
needle proteins.
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Alignment Report of needle proteins2.meg J. Hein (PAM250)
Wednesday, March 20, 2013 9:46 AM

Page 1

+ Majority
Majority

M-----------------------------------------DIS-TXDDXXXXL-------NKQVXDAIXALA--TNPD
10

YpYscF
PrgI
SsaG
MXIH_SHIFL
PscF
AhYscF
VparaYscF
BsaL
EscF

20

30

40

50

60

70

80

M---------SNFSGFTKGT----------------------DIA-DLDAVAQTLKKPADDANKAVNDSIAALK--DKPD
M---------------------------ATP-----WSGYLDDVSAKFDTGVDNL-------QTQVTEALDKLA--AKPS
M-----------------------------------------DIAQLVDMLSHM--------AHQAGQAINDKM--NGND
M---------------------------SVTVPNDDWT--LSSLSETFDDGTQTL-------QGELTLALDKLA--KNPS
MAQ--IFNPN--------------------------------PGN-TLDTVANALKEQANAANKDVNDAIKALQGTDNAD
MADYFTYTDK--------------------------------NSN-TLDQVATNLSGQANTANTEVNKAIEAMK--TNPD
MS---FYDAT--------------------------------NSV-NLDDVKTKLEQQAKDANKSVTDAIKNLE--TNAD
D-------------------YEWSGYLT--------------GIGRAFDDGVKDL-------NKQLQDAQANLT--KNPS
M-----------------------------------------DISKQFDQGVDDL-------NQQVEKALEDLA--TNPS

46
39
29
42
45
45
42
38
30

+ Majority
Majority

--NPALLAEXQHKXNXYSXYXNXXSTXVKAXKDLXQGIXQKFR
90

YpYscF
PrgI
SsaG
MXIH_SHIFL
PscF
AhYscF
VparaYscF
BsaL
EscF

100

110

120

--NPALLADLQHSINKWSVIYNINSTIVRSMKDLMQGILQKFP
--DPALLAAYQSKLSEYNLYRNAQSNTVKVFKDIDAAIIQNFR
LLNPESMIKAQFALQQYSTFINYESSLIKMIKDMLSGIIAKI
--NPQLLAEYQSKLSEYTLYRNAQSNTVKVIKDVDAAIIQNFR
--NPALLAELQHKINKWSVIYNINSTVTRALRDLMQGILQK-I
--NPALLAELQHKINKWSVIYNINSTVTRAMKDLMQGILQK-I
--DPSKLAELQHAINKWSVVYNINATTTRAIKDVMQSILQK-V
--DPTALANYQMIMSEYNLYRNAQSSAVKSMKDIDSSIVSNFR
--DPKFLAEYQSALAEYTLYRNAQSNVVKAYKDLDSAIIQNFR

87
80
71
83
85
85
82
79
71

Decoration 'Decoration #1': Shade (with bright yellow at 50% fill) residues that match the
Consensus exactly.
Decoration 'Decoration #2': Shade (with bright yellow at 50% fill) residues that match the
Consensus exactly.

Figure 22. Needle proteins multiple sequence alignment demonstrates that the N-termini of
T3S needle proteins are not conserved.
Needle protein sequences from several species of bacteria were aligned, using the
Jotun Hein algorithm with the PAM250 matrix, with Megalign from the DNAStar
Lasergene package (v. 10.1). Identical residues are shown in shaded boxes. Aligned
needle proteins are from Yersinia pestis, Yersinia pseudotuberculosis, Yersinia
enterocolitica, Salmonella enterica (both PrgI and SsaG), Shigella flexneri,
Pseudomonas aeruginosa, Aeromonas hydrophila, Vibrio parahaemolyticus, Burkolderia
pseudomallei, and E. coli.
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Response of THP-1 Cells to Needle Proteins
Evaluation of cellular responses to recombinant whole needle proteins and
truncated forms of needle proteins by THP-1 X-Blue cells was accomplished by
measuring SEAP production. SEAP expression is under control of NF-κB and
AP-1, key transcription factors, that activate cytokine and chemokine expression
critical for innate immune responses. Therefore an increase in SEAP equated to
an increase in NF- κB and/or AP-1 activity. All proteins were applied at 1 µg/ml to
cells. Full length MxiH significantly activated NF- κB/AP-1 as well as truncated
forms of YscF and PrgI (Figure 23A). Whole YscF, PrgI, and truncated MxiH
significantly activated cells; however, these proteins had lower levels of activation
than their counterparts (Figure 23A). These results show that the truncated forms
of YscF and PrgI increase NF-κB/AP-1 activation to higher levels in comparison
to the full-length proteins. SsaG, which is only expressed within eukaryotic cells,
activates cells only slightly more than the truncated form. The responses to the
N-terminal truncations of YscF and PrgI suggest there may be a hidden hostactivating element, whereas, the presence of the N-terminus of MxiH appears to
increase interaction of MxiH and Thp-1 X-Blue cells.
When the proteins were incubated with THP-1 X-Blue cells deficient in
MyD88, an adaptor protein required for TLR response, the activation of NFκB/AP-1 was abolished (Figure 23B). The lack of response by cells lacking
MyD88 indicates that the response is likely occurring through TLR recognition of
the needle proteins.
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A.

B.

Figure 23. Activation of NF-kB in THP-1 X-Blue cells by needle proteins is MyD88 dependent.
THP-1 (A) and THP-1 defMyd88 (B) cells were seeded in wells and treated with PBS, HKLM
(Heat Killed Listeria monocytogenes), LPS, Flagellin, Tri-DAP, or 1ug/ml of needle protein
dissolved in PBS. SEAP levels were measured as representation of NFkB activation.
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THP-1 response to digested needle proteins
Needle proteins and flagellin digested with proteinase K were added to
THP-1 X-Blue cells to confirm that proteins were activating NF-κB/AP-1 (Figure
24). Proteinase K is a serine protease that cleaves after hydrophobic amino
acids. Proteinase K in PBS was used as a negative control. As expected, flagellin
(a TLR5 agonist; positive control) treated with proteinase K abrogated the NFκB/AP-1 response and proteinase K alone did not activate NF-κB/AP-1. These
data demonstrate that the proteinase K used did not contain a TLR agonist and
that, as expected, proteinase K treatment eliminated the ability of flagellin to
activate NF-kB/Ap-1 (Figure 24). The proteinase K (Figure 24) treated needle
proteins also failed to illicit NF-κB/AP-1 activation; confirming that proteins are
causing the cellular activation of NF-κB/AP-1.

Figure 24. Activation of NF-kB in THP-1 X-Blue cells by needle proteins is abrogated
by proteinase K digestion of needle proteins.
Proteins, as well as PBS and Flagellin, were digested with Proteinase K before
incubation with THP-1 X-Blue cells. SEAP levels were measured as a
representation of NF-kB activation.
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LPS assay of needle proteins and equivalent responses by THP-1 X-Blue
cells
LPS levels were analyzed to evaluate potential contamination of the
needle protein samples. All samples had approximately 1 EU/mL of LPS (Figure
25A). To determine if 1 EU/mL of LPS had a significant effect on NF-κB/AP-1
activation, the standard concentrations of LPS from the kit were used to treat
THP-1 X-Blue cells. The results indicated that 1 EU/mL of LPS did not activate
NF-κB/AP-1 (Figure 25B). Therefore the level of LPS in the needle protein
samples is not a factor in the activation levels seen in Figure 23.
A.

Figure 25. LPS contamination of
needle proteins is
minimal.
An LPS kit was used to
analyze the level of LPS
contamination in the
needle protein preps (A).
The standard LPS levels
were used to treat THP-1
X-Blue cells (B). SEAP
levels were measured as
representation of NFkB
activation.

B.
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TLR Expressing HEK 293 cells response to needle proteins
To elucidate the TLRs that needle proteins could signal through, an initial
screening for TLR interaction was conducted by Invivogen. HEK 293 reporter
cells transfected with a selected TLR were incubated with YscF and trYscF (data
not shown). These results indicated HEK 293 cells expressing TLR2 or TLR4
responded to whole and truncated forms of YscF. The NF-kB reporter in HEK
293 cells expressing TLRs 3, 5, 7, 8, or 9 did not respond to YscF or trYscF. The
reporter in the HEK 293 cells responded more strongly to trYscF than full length
YscF, confirming our original observations with THP-1 X-Blue cells.
To further test this result, HEK 293 cells transfected with TLR2, TLR4, or
TLR5 were acquired and used to assess the needle proteins from other bacterial
species as well. TLR2 expressing HEK 293 cells showed a similar pattern as
seen with the THP-1 X-Blue cells where all proteins activated NF-κB/AP-1
(Figure 26A). Specifically, truncated forms of YscF and PrgI activated NF-κB/AP1 more than full length YscF and PrgI. MxiH and SsaG behaved oppositely than
the other proteins, with full length MxiH and SsaG activating slightly more than
the truncated forms.
TLR4 expressing HEK 293 cells also reacted to all the tested needle
proteins (Figure 26B). YscF activated slightly less than trYscF. PrgI activated
less than trPrgI, similar as was observed with THP-1 X-Blue and HEK TLR2
cells. MxiH activated more than trMxiH, again similar to the other cell types.
SsaG activated slightly less than trSsaG, contrary to previous cell types.
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A.

B.

C.

Figure 26. TLR2 and/or TLR4 are necessary for activation of NF-kB by needle proteins
in HEK293 cells expressing TLR2, TLR4, or TLR5.
HEK cells that express one particular TLR were tested with 1ug/ml of needle proteins
dissolved in PBS. HKLM was used as a control for TLR2 (A). LPS was the positive
control for TLR4 (B). Flagellin was the positive control for TLR5 (C). SEAP levels
were measured as representation of NFkB activation.
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Since the HEK293/TLR2 and HEK293/TLR4 cells endogenously express
TLR5, we also tested TLR5 expressing HEK 293 cells. TLR5 expressing cells
showed no response to any of the needle proteins indicating that the proteins
were specifically targeting TLR2 and TLR4 (Figure 26C). Taken together the data
support the idea that needle proteins are recognized as a PAMP by TLR2 and
potentially TLR4. Additionally, needle proteins from different bacteria trigger
responses of varying magnitude and finally that the N-terminus of some needleproteins alters the responses by TLRs.

TLR2 Antibodies block activation by needle proteins to TLR2 expressing
HEK 293 cells
Antibodies to TLR2 were utilized to assess interaction of needle proteins
with TLR2 in HEK293/TLR2 cells. Control antibodies and TLR2 antibodies were
administered at equal concentration to HEK293 cell cultures. Administration of
the isotype control antibodies followed by subsequent incubation with needle
proteins (YscF, trYscF, PrgI, trPrgI, MxiH, trMxiH, SsaG, and trSsaG) resulted in
no significant decrease to NF-κB/AP-1 activation by the needle proteins (Figure
27). After treatment of the cell cultures with TLR2 antibody and subsequent
incubation with needle proteins (Figure 27), NF- κB/AP-1 activation was
significantly decreased when compared to control antibody in the case of trYscF,
PrgI, trPrgI, MxiH, trMxiH, SsaG, and trSsaG (Figure 27). YscF was not
significantly decreased (Figure 27); however, YscF alone had low activation of
NF-κB/AP-1 (Figure 27). These results confirm that the needle-proteins are
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activating NF-κB and/or AP-1 through TLR2 as neutralization of TLR2 with
antibodies abrogated the needle protein induced response in the HEK293/TLR2
cells.

Figure 27. Antibody to TLR2 blocks NF-kB activation in response to needle proteins in
HEK293 cells expressing TLR2 cells.
HEK TLR2 cells were treated with HKLM or needle proteins after no treatment, an
antibody control, or antibody to TLR2. SEAP levels were measured as representation of NFkB
activation.	
  

TLR4 inhibitor CL1-095 inhibits response of THP-1 cells
TLR4 inhibitor CL1-095 was used to treat THP-1 cells prior to treatment
with LPS, flagellin, or needle proteins (YscF, trYscF, PrgI, trPrgI, MxiH, trMxiH,
SsaG, and trSsaG). Cells left untreated with CL1-095 reacted to LPS or proteins
in the same pattern as seen in Figure 28. Those cells treated with CL1-095 did
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not react to LPS. Reaction to flagellin was left intact, as expected, and reaction to
needle proteins was in all cases significantly reduced, although not quite to basal
levels, suggesting that activation of THP-1 cells by needle proteins can be
reduced by antagonizing TLR4.

Figure 28. The TLR4 inhibitor CL1-095 blocks activation of NF-kB by needle proteins in THP-1
X-Blue cells.
THP-1 cells were treated with PBS, LPS, Flagellin, or needle proteins. Prior to treatment
cells were either left untreated or treated with TLR4 inhibitor CL1-095. SEAP levels were
measured as representation of NFkB activation.

TNF-α expression in response to needle proteins
THP-1 X-Blue cells were treated with PBS, LPS, full length and truncated
forms of needle proteins. After 5 hours supernatants were collected and
assessed via ELISA for TNF-α production. As expected, PBS treated cells
produced no TNF-α and LPS treatment led to production of TNF-α (Figure 29).
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Truncated forms of YscF produced significantly more TNF-α than full-length
forms of YscF, consistent with the assays for NF-κB/AP-1 activation. Full length
YscF did induce TNF-α but to a lower extent than trYscF. PrgI induced TNF-α
however trPrgI induced slightly more (Figure 29). MxiH induced more TNF-α than
trMxiH, which agrees with previous data indicating MxiH activated NF-κB/AP-1
more than trMxiH. SsaG induced more TNF-α than trSsaG, which also correlates
with our NF-κB/AP-1 data. These results indicate that the increases in NF-κB
activation seen consequentially leads to an increase in TNF-α levels in cell
culture supernatants.

Figure 29. Activation of THP-1 X-Blue cells by needle proteins results in TNF-α
secretion.
THP-1 cells were treated with PBS, LPS, or needle proteins. After 5 hours
supernatants were collected and tested by ELISA for production of TNFα.
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CHAPTER IV
DISCUSSION

To understand and combat disease, a multifaceted approach must be
taken to advance our knowledge ahead of the pathogen evolution to evade our
treatments. The two projects described here present a multifaceted approach to
understanding Y. pestis virulence. Bacteria manipulate the host immune system
in a targeted manner to cause disease, this manipulation is shown by the
modulation of host response by the N-termini of T3SS needle proteins. These
manipulations of the host immune system give an advantage to the bacterium.
However, gaining understanding of how these manipulations occur can allow
science to develop new treatments to contest the bacteria by giving the host
immune system the advantage. Currently, new treatments such as smallmolecule inhibitors to T3SS, are being developed as anti-virulence therapies in
contrast to the traditional anti-metabolic and anti-biosynthetic strategies that
fueled the development of modern antibiotics. Inhibiting the T3SS, a major
virulence factor in many human gram-negative bacteria, leaves the pathogen
unable to modulate the host immune response as effectively and allows the host
to mount a successful attack on the bacteria. This method allows the immune
system to effectively clear the pathogen itself without affecting the natural
microbiome of the host, and also reduces the selective pressure that antibiotics
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create (21). N-terminally truncated needle proteins could be developed as
adjuvants or immune modulators, again shifting the advantage to the host. If host
immune cells can be primed to react with N-terminally truncated needle proteins,
then the host could either respond better to vaccinations or jump-start a host
response to a current infection. In the current arms race we are engaged in with
pathogens, advancement on many fronts will be the key to staying ahead of our
adversaries.
Consequently, in researching two aspects of the T3SS, there are
implications to the system that each project uniquely uncovers. Compound D,
was shown to effectively inhibit the secretion of toxins in a family of T3SSs. This
effect was mediated through YopD and possibly LcrQ and LcrH, and also
required a secretion active conformational state of the T3SS. Compound D also
revealed a functional difference between secretion by calcium blind strains in the
presence and absence of calcium. Studies into the host response to needle
proteins revealed that these proteins have the ability to activate host cells
through TLR2 and TLR4 and that the N-terminus may modulate that interaction.

Compound D
Studies with Compound D show that Yops secretion in Y. pestis is
inhibited by Compound D. LcrV was secreted prior to the Compound D-mediated
blockage of the T3S system, indicating the secretion apparatus is functional due
to its ability to secrete LcrV; however, no proteins after LcrV are secreted. This
inhibition of Yops secretion requires YopD and results show that YopD was able
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to pull Compound D out of solution, implying a direct interaction between the two.
LcrQ and LcrH appear to also play a role in inhibition.
YopD is unique when compared to other identified targets of T3S systems,
such as LcrF, ExsA, YscN and other suspected proteins of the T3S apparatus or
membrane rings (34, 41, 43, 100, 106). These targeted proteins alter the T3S
basal structural components or expression of the apparatus genes, as opposed
to YopD, a translocon protein, presumably an early secreted protein also known
to play a role in the regulation of expression of other Yops (14). YopD’s
regulatory role is shared with its chaperone LcrH, which is also needed for
effective delivery of YopD to the secretion apparatus (37). The regulatory role of
YopD and LcrH revolves around Yops translation. This protein pair may interact
with mRNA of Yops and prevent their translation (20). Thus, when either of
these proteins is deleted, Yop expression increases (37). However, the
involvement of YopD/LcrH in Yop expression is difficult to separate from
secretion induced Yop expression (32). Therefore, to elucidate whether
Compound D was affecting regulation or simply physically blocking secretion
becomes difficult.
In order to begin clarifying the mechanism of Compound D inhibition,
several factors were investigated. Beginning at the level of transcription, a YopEchimera, expressed under the control of a non-LCR regulated promoter, was not
secreted in the presence of Compound D, implying the inhibitor is able to block
secretion of a protein not under LCR control. The YopE-chimera was produced
using the araBADp promoter, creating a large cellular pool of the protein, which
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still could not overcome the inhibition of Compound D, suggesting that a physical
blockage of the apparatus is possible. This result suggests that Compound D is
working at the level of secretion and not at the level of LCR regulation. The hyper
production of Yops in a YopD mutant presents the idea that Compound D could
be overwhelmed by YopD production to restore Yops secretion despite the
presence of the inhibitor. This assertion proved false, requiring cooverexpression of YopD and its chaperone LcrH, and suggests YopD may not be
the only protein required for Compound D mediated secretion inhibition.
The involvement of LcrH and LcrQ is perplexing in that both proteins are
known to play multiple roles that are hard to distinguish from each other and
YopD in deletion mutants. LcrH is known to be required not only for regulation
but also for effective YopD and YopB delivery to the secretion apparatus.
Therefore, the result of inhibition of YopE secretion, but not YopM secretion, by
Compound D in the lcrH mutant can be interpreted multiple ways. Due to the
regulatory role LcrH performs in combination with YopD in decreasing Yops
translation, the lack of LcrH could affect the production of Yops. Although, this
effect was only seen on YopE, since YopM was produced and secreted in this
mutant. These results imply that either LcrH/YopD regulation does not equally
affect all Yops or that the regulatory role is not significant for Compound D
inhibition. The lack of LcrH could also affect YopD’s delivery to the apparatus,
although this is also confounded by the secretion of YopM but not YopE. Notably,
overexpression of LcrH in figures 13 and 14 caused a dramatic decrease in
cellular expression of Yops and subsequently no secretion. This was not in
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conjunction with Compound D as this occurred in the absence of the inhibitor.
Compound D inhibition occurs through YopD but is affected by LcrH, and in a
non-LCR dependent manner.
LcrQ is also proposed to have multiple functions in the T3S system. WulffStrobel et al. propose that LcrQ plays a role in regulation of Yops secretion at the
level of the “ysc gate” (110). This regulatory function is thought to determine
substrate specificity at the gate of the apparatus, affecting the hierarchy of Yops
secretion (110). If Compound D is affecting YopD and preventing secretion at
the site of the “Ysc gate”, it is possible that the lack of LcrQ at the gate may alter
the mechanism of inhibition. However, others propose that LcrQ function is
similar to YopD/LcrH function to regulate Yop production (19, 85). Similar to the
lcrH mutant, Compound D’s effect on the lcrQ mutant was more pronounced on
YopE than YopM. It is note worthy that YopM does not require a chaperone while
YopE does (104). Whether chaperones play a factor in secretion of Yops at the
“ysc gate” has yet to be elucidated; although their role in determining the
secretion hierarchy has been implicated by Boyd et al (9). Therefore, the results
of LcrH and LcrQ affecting the production of YopE support the idea of a
regulatory role being affected by Compound D to inhibit secretion. However, the
lack of effect on YopM production could imply regulation by these proteins is
either not equal, or the involvement of LcrH and LcrQ in inhibition by Compound
D is much more complex and requires further study.
The ability of Compound D to affect effector secretion in Pseudomonas
aeruginosa argues that the inhibition of Yops secretion by Compound D is not
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directed at the regulatory effects of YopD. Broms et al. showed that PopD was
unable to substitute for YopD in the Yersinia system due to its lack of regulatory
function (14). Compound D’s ability to affect secretion in P. aeruginosa indicates
the regulatory function is not required for inhibiting secretion. These results
suggest Compound D does not affect the regulatory role YopD plays in secretion
but rather that Compound D works at the level of secretion through YopD.
The calcium blind strains, caused by disrupted regulation, exposed to
Compound D revealed that the inhibitor could only successfully inhibit secretion
with these particular strains in the environment lacking calcium. However, a
calcium blind YscF D46A mutant strain indicated this was not due to a calcium
effect on Compound D but likely due to a change in the secretion system. These
results support the hypothesis that the removal of calcium results in a functional
change in the Ysc apparatus to allow secretion and that this change involves the
needle protein YscF (8). Torruellas et al. discovered mutations in YscF that allow
for constitutive secretion, implying that the needle protein plays a role in calcium
sensing or transmission of the calcium sensing signal to the basal structure
(102). In the case of regulatory calcium blind strains (e.g. loss of LcrG or YopN
function), the ability of Compound D to work in one environment and not the
other implies that secretion in the presence and absence of calcium do not occur
in the same manner. The removal of the regulator (LcrG or YopN) alone allows
secretion by the system in the presence of calcium. While in the absence of
calcium, a change in the secretion apparatus still occurs through the calcium
sensing mechanism; Compound D may affect that signaling. The requirement of
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an “active secretion state” for Compound D to inhibit secretion implies the
mechanism of inhibition occurs at the apparatus and not at the regulatory roles of
YopD, LcrH, or LcrQ.
The proposed model of inhibition by Compound D includes an interaction
with YopD, which is affected by LcrH and LcrQ, and does not involve secretion
regulatory proteins LcrG, LcrV, YopN, YscB, SycN. Inhibition of the T3SS can still
occur for proteins not under LCR expression and regulation. The inhibition does
require the sensing of calcium and the subsequent alteration in the needle
apparatus. Given these results we propose the following model of inhibition by
Compound D, where Compound D’s effect occurs at the site of secretion (Figure
30). The elucidation of detached control upon secretion in calcium blind strains
led us to develop a separate model (Figure 31). In this model of the calcium blind
strains, secretion occurs despite the absence of a signal in the presence of
calcium, while in the YscF D46A the mutation signals for secretion in both
calcium environments, which allows Compound D to inhibit secretion in both
cases.
Interestingly the T3SS inhibitor Compound 2, an isoform of Compound D,
discovered by Pan et al. (83) does not work in the same manner. Deletion of
neither translocon proteins, YopD or YopB, alleviated Compound 2’s ability to
inhibit secretion, nor did Compound 2 have the same effect on constitutive
secretors, as it inhibited both in the presence and absence of calcium. Although
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Figure 30. Mechanism for Compound D inhibition in Yersinia pestis T3SS
(A) Diagram of T3SS in the presence of calcium. Secretion is regulated by LcrG and YopN while
Yop translation is prevented by YopD/LcrH and no secretion occurs (B) Diagram of T3SS in the absence
of calcium. Calcium signal initiates secretion, LcrG is titrated away by LcrV, YopN is secreted, Yop
translation is released from YopD/LcrH and Yops are secreted into medium. (C) Compound D is present
however secretion is regulated by LcrG and YopN while Yop translation is prevented by YopD/LcrH and
no secretion occurs. (D) In the presence of Compound D the calcium signal initiates secretion however
YopD/Compound D blocks secretion at the “Ysc gate”. Translation of Yops is still inhibited because YopD
levels are not lowered by secretion.
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Figure 31. Mechanism for Compound D inhibition of calcium blind Yersinia pestis T3SS
strains.
(A) Calcium blind strains lacking LcrG/YopN secrete Yops into the medium despite the presence of
calcium and lack of a secretion signal. (B-C) YscF(D46A) is mutated to a locked position of sending a
calcium signal, in the presence of Compound D this allows secretion to be inhibited no matter if
calcium is present or not.
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both compounds are able to target the T3SS in multiple strains of bacteria, they
fascinatingly inhibit secretion in completely separate ways.
Unfortunately both compounds were found to be toxic: Compound 2
caused cell rounding and detachment and LDH release (83) and high serum
protein binding (1), while Compound D was capable of lysing red-blood cells
making translocation analysis in the presence of the inhibitor impossible. This
also means these two compounds without modification would be poor candidates
as potential antimicrobials. However, the unique manner in which Compound D
inhibits secretion may lead us to a greater understanding of the complex
regulation of this system and give insight on the deeply intertwined structural role
the apparatus plays in regulation of secretion.

Host response to T3SS needle proteins
Characterization of the needle protein’s (MxiH, SsaG, YscF, and PrgI)
ability to induce innate immune factors revealed: 1) NF-kB/AP-1 is activated by
needle proteins or portions of needle proteins. 2) Activation of NF-kB/AP-1 by
needle proteins is dependent upon MyD88. 3) Activation occurred exclusively
through TLR2 and TLR4. 4) Observed variation in the N-terminus of needle
proteins appears to modify the interaction with TLRs.
YscF comes from the T3SS of bacteria that have anti-inflammatory
infection objectives. This needle protein elicits lower levels of NF-kB/AP-1
activation and TNF-α; however, the N-terminally truncated forms have the
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opposite effect and induce higher NF-kB/AP-1 activation as well as TNF-α.
Interestingly, a similar phenomenon is seen with flagellin and its homologs. The Nterminus of flagellin is involved in immune evasion by some bacteria (Helicobacter,
Campylobacter and Bartonella) (3).
Shigella and Salmonella are known to cause largely pro-inflammatory
responses to the host in order to cause disease (52, 86). The Shigella needleprotein, MxiH, acted in accordance to this overarching goal of infection; as it
induced increased NF-kB/AP-1 and TNF-α as a full-length protein. Removal of
the N-terminus of MxiH actually attenuated the cellular response, indicating that
the N-terminus positively adds to the pro-inflammatory environment by activating
TLRs. Unexpectedly, PrgI acted similarly to YscF, less inflammatory in its natural
state. It is possible other factors play a larger role in the fine-tuned proinflammatory response to Salmonella.
The Salmonella SPI-2 needle protein SsaG more equally activated in its
full-length form and after N-terminal truncation. SsaG is already “naturally”
truncated when compared to other needle proteins. Under our hypothesis that
the N-termini of needle proteins modulate TLR interaction, there would be no
need for an extended N-terminus because SsaG is not exposed to TLRs
expressed on the outside of the host cell, since SPI-2 is only expressed once
Salmonella is enclosed in the Salmonella Containing Vacuole (13) inside the
host cell. Exposure to host TLRs may create pressures for the N-terminus of
needle proteins to modulate host responses.

	
  

84	
  

TLR4 is already known to play a unique role in Yersinia pestis
pathogenesis because Yersinia pestis produces a tetra-acylated LPS (53). This
change in acylation results in weaker TLR4 stimulation and subsequent deficient
activation of the immune system, keeping the bacteria under the host’s radar
(101). TLR4’s role in recognition of needle proteins was less expected than the
more promiscuous TLR2. However, there are several documented cases of
TLR4 interaction with pathogen associated substrates other than LPS:
Respiratory Syncytial Virus (RSV) fusion protein (89), chlamydial Hsp60 (17),
pneumolysin (64), Francisella tularensis DnaK (4), and Ebola virus glycoprotein
(81), and cell wall components from Pseudallescheria boydii (35). Many of these
pathogen associated molecular patterns (PAMPs) are well characterized as to
the exact method of interaction with TLR4, and future research in our lab will
hopefully elucidate how needle proteins interact with TLR4, including whether
MD-2 or CD-14 is required for this interaction.
The Neisserial porin, PorB, is also a surface exposed protein. PorB is
highly conserved among Neisseria species, except for the surface exposed
loops. Much like T3S needle proteins, PorB, specifically the exposed loops, were
found to interact with TLR2. The interaction with TLR2 was found to be
dependent on specific amino acids and the variation between PorB of different
Neisseria species creates unique “TLR2 binding signatures”. Specific binding
signatures were found to be more or less inflammatory through interaction with
TLR2 (61, 65, 103). We propose that the T3SS needle proteins N-terminal
variation between species acts similar to PorB, in that the unique surface
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exposed N-terminus creates a unique binding signature, which modulates the
host response to the bacteria.
Currently, we do not know the specifics of which amino acid sequences
play a role in interactions with TLRs. We cannot at this time rule out the
possibility that the binding signature is created by a change in protein structure,
which could also be affected by the his-tag, as opposed to specific amino acid
sequences. However, this research does describe a new class of PAMP that
interacts with TLRs in an unexpected manner. This discovery has the potential to
increase our understanding of host responses to T3S utilizing pathogens and to
extend our knowledge of how other host processes may interact with T3S
apparatuses.
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